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A B S T R A C T
Background
Dehydration is an important cause of death in patients with Ebola virus disease (EVD). Parenteral fluids are often required in patients
with fluid requirements in excess of their oral intake. The peripheral intravenous route is the most commonly used method of parenteral
access, but inserting andmaintaining an intravenous line can be challenging in the context of EVD. Therefore it is important to consider
the advantages and disadvantages of different routes for achieving parenteral access (e.g. intravenous, intraosseous, subcutaneous and
intraperitoneal).
Objectives
To compare the reliability, ease of use and speed of insertion of different parenteral access methods.
Search methods
We ran the search on 17 November 2014. We searched the Cochrane Injuries Group’s Specialised Register, Cochrane Central Register of
Controlled Trials (CENTRAL, The Cochrane Library), Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MED-
LINE(R) Daily, Ovid MEDLINE(R) and Ovid OLDMEDLINE(R), Embase Classic + Embase (OvidSP), CINAHL (EBSCOhost),
clinicaltrials.gov and screened reference lists.
Selection criteria
Randomised controlled trials comparing different parenteral routes for the infusion of fluids or medication.
Data collection and analysis
Two review authors examined the titles and abstracts of records obtained by searching the electronic databases to determine eligibility.
Two review authors extracted data from the included trials and assessed the risk of bias. Outcome measures of interest were success
of insertion; time required for insertion; number of insertion attempts; number of dislodgements; time period with functional access;
local site reactions; clinicians’ perception of ease of administration; needlestick injury to healthcare workers; patients’ discomfort; and
mortality. For trials involving the administration of fluids we also collected data on the volume of fluid infused, changes in serum
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electrolytes and markers of renal function. We rated the quality of the evidence as ’high’, ’moderate’, ’low’ or ’very low’ according to
the GRADE approach for the following outcomes: success of insertion, time required for insertion, number of dislodgements, volume
of fluid infused and needlestick injuries.
Main results
We included 17 trials involving 885 participants. Parenteral access was used to infuse fluids in 11 trials and medications in six trials.
None of the trials involved patients with EVD. Intravenous and intraosseous access was compared in four trials; intravenous and
subcutaneous access in 11; peripheral intravenous and intraperitoneal access in one; saphenous vein cutdown and intraosseous access
in one; and intraperitoneal with subcutaneous access in one. All of the trials assessing the intravenous method involved peripheral
intravenous access.
We judged few trials to be at low risk of bias for any of the assessed domains.
Compared to the intraosseous group, patients in the intravenous group were more likely to experience an insertion failure (risk ratio
(RR) 3.89, 95% confidence interval (CI) 2.39 to 6.33; n = 242; GRADE rating: low). We did not pool data for time to insertion
but estimates from the trials suggest that inserting intravenous access takes longer (GRADE rating: moderate). Clinicians judged the
intravenous route to be easier to insert (RR 0.15, 95% CI 0.04 to 0.61; n = 182). A larger volume of fluids was infused via the
intravenous route (GRADE rating: moderate). There was no evidence of a difference between the two routes for any other outcomes,
including adverse events.
Compared to the subcutaneous group, patients in the intravenous group were more likely to experience an insertion failure (RR 14.79,
95% CI 2.87 to 76.08; n = 238; GRADE rating: moderate) and dislodgement of the device (RR 3.78, 95% CI 1.16 to 12.34; n = 67;
GRADE rating: low). Clinicians also judged the intravenous route as being more difficult to insert and patients were more likely to
be agitated in the intravenous group. Patients in the intravenous group were more likely to develop a local infection and phlebitis, but
were less likely to develop erythema, oedema or swelling than those in the subcutaneous group. A larger volume of fluids was infused
into patients via the intravenous route. There was no evidence of a difference between the two routes for any other outcome.
There were insufficient data to reliably determine if the risk of insertion failure differed between the saphenous vein cutdown (SVC) and
intraosseous method (RR 4.00, 95% CI 0.51 to 31.13; GRADE rating: low). Insertion using SVC took longer than the intraosseous
method (MD 219.60 seconds, 95% CI 135.44 to 303.76; GRADE rating: moderate). There were no data and therefore there was no
evidence of a difference between the two routes for any other outcome.
There were insufficient data to reliably determine the relative effects of intraperitoneal or central intravenous access relative to any other
parenteral access method.
Authors’ conclusions
There are several different ways of achieving parenteral access in patients who are unable meet their fluid requirements with oral intake
alone. The quality of the evidence, as assessed using the GRADE criteria, is somewhat limited because of the lack of adequately powered
trials at low risk of bias. However, we believe that there is sufficient evidence to draw the following conclusions: if peripheral intravenous
access can be achieved easily, this allows infusion of larger volumes of fluid than other routes; but if this is not possible, the intraosseous
and subcutaneous routes are viable alternatives. The subcutaneous route may be suitable for patients who are not severely dehydrated
but in whom ongoing fluid losses cannot be met by oral intake.
A film to accompany this review can be viewed here (http://youtu.be/ArVPzkf93ng).
P L A I N L A N G U A G E S U M M A R Y
Comparison of the different ways of giving fluids to patients who cannot drink enough, such as patients with Ebola virus
disease
Background
Many patients with Ebola virus disease (EVD) die because they are dehydrated. Patients with EVD often experience severe vomiting
and diarrhoea, which causes them to lose fluids that are difficult to replace by drinking alone. It is possible to give fluids in ways that
do not involve the digestive tract; this is known as parenteral access. This includes infusing fluids into a vein (intravenously), into bone
marrow (intraosseously), into fatty tissue under the skin (subcutaneously) or into the abdominal space (intraperitoneally). Giving fluids
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intravenously is the usual method, but can be problematic in patients with EVD because starting intravenous fluids can be difficult in
very dehydrated patients, and infection control practices may make maintaining the infusion challenging. It is therefore useful if those
caring for patients with EVD know the advantages and disadvantages of the other ways to give fluids, so that they can decide which is
the most suitable for their patients.
Searches for trials
We carried out searches for trials comparing different parenteral access methods on 17 November 2014.
Trial characteristics
We found 17 trials involving 885 participants. None involved patients with EVD. Fifteen trials involved patients who required parenteral
access for the infusion of fluids or medicines and two trials assessed different methods under simulated conditions, such as on a training
manikin. Many trials were of poor quality.
Key results
When the results of these trials were gathered together, they suggested that both the intraosseous and subcutaneous routes may be easier
and quicker to insert into patients than the intravenous route, but more fluid can be given intravenously than by either the intraosseous
or subcutaneous method. There has not been enough research into the intraperitoneal method to know how it compares to the other
methods.
Conclusions
Healthcare workers caring for patients with EVD should be aware of the alternative ways of giving fluids. The trials we found were not
of very high quality, therefore we need to be cautious when drawing conclusions based on their results. However, together they suggest
if intravenous access can be achieved easily, then this should be used as it allows the infusion of larger volumes of fluid. However, if
intravenous access is not possible, intraosseous and subcutaneous routes are alternatives that can be inserted quickly. Many of the trials
conducted so far are of poor quality and none involved patients with EVD, therefore more trials should be carried out.
A film to accompany this review can be viewed here.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Intravenous versus intraosseous route for achieving parenteral access
Patient or population: adults or children requiring fluid delivered by a parenteral route (one study testing insertion and the volume of fluid delivered in manikins by practitioners wearing
protective equipment was also included)
Settings: India (emergency unit) and USA (pre-hospital care)
Intervention: intravenous route
Comparison: intraosseous route
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Intraosseous route Intravenous route
Insertion failures Study population RR 3.89
(2.39 to 6.33)
242
(2 RCTs)
⊕⊕©©
LOW 1,2
-
12 per 100 47 per 100
(29 to 76)
Time to infusion/place-
ment
We did not combine data due to substantial variation
in the average time taken to insert parenteral access
between trials. The estimates from all 4 trials suggest
that the IV route takes longer to insert than IO.
Although we are confident that the time to infusion is
shorter with IO, we cannot be certain about the size
of the effect because the magnitude of the difference
varied considerably between trials
- 342
(4 RCTs)
⊕⊕⊕©
MODERATE 1,
-
Dislodgement of device
during infusion
Study population RR 0.53
(0.18 to 1.55)
182
(1 RCT)
⊕⊕©©
LOW 1,3
-
113 per 1000 60 per 1000
(20 to 175)
Needlestick injuries No studies reported this
outcome
No studies reported this
outcome
- NA NA -
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Volume of fluid infused The mean volume of fluid
infused (ml) in the IO
group was 800
The mean volume of
fluid infused (ml) in
the IV group was 400
higher (365 higher to 434
higher)
- 182
(1 RCT)
⊕⊕⊕©
MODERATE 1
-
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; IO: intraosseous; IV: intravenous; NA: not applicable; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded one level for risk of bias: estimate based on trial(s) at unclear and/or high risk of bias for ≥ 1 domain.
2Downgraded one level for imprecision: estimate is statistically significant at the 5% level (P value <0.001); however, the estimated
required information size has not been achieved and we cannot discount the possibility that it is a false positive.
3Downgraded one level for imprecision: estimate based on few events and wide CIs that include both an increase and a decrease in risk.
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B A C K G R O U N D
Description of the condition
Ebola virus disease (EVD) is a severe infection with a high case-
fatality rate (WHO Ebola Response Team 2014). West Africa is
currently (November 2014) experiencing the largest recorded out-
break of EVD with many hundreds of new cases per week (WHO
Ebola Response Team 2014). EVD is characterised by sudden on-
set of fever followed by nausea, vomiting and diarrhoea. The asso-
ciated fluid loss, which can be as much as five to 10 litres per day
(Kreuels 2014; Ribner 2014), leads to electrolyte abnormalities
and profound intravascular volume depletion (Feldmann 2011;
Sanchez 2006). Case series show that in people with fatal EVD,
blood levels of urea and creatinine increase over time, which may
be a consequence of dehydration (Schieffelin 2014). Fluid admin-
istration is therefore recommended as a key part of supportive care
to reduce mortality in patients with EVD (WHO 2014).
Description of the intervention
Many patients with EVD have nausea, difficulty swallowing and
severe vomiting, which limit the usefulness of oral rehydration.
Similarly, severe diarrhoea limits the usefulness of rectal fluid ad-
ministration. In these patients, parenteral fluids can be given to
prevent and treat dehydration.
There are four main ways of achieving parenteral access to admin-
ister fluids: intravenous, intraosseous, subcutaneous and intraperi-
toneal.
• Intravenous access involves the delivery of fluids or
medications directly into a vein. There are two types of venous
access - central and peripheral. Central venous catheters involve
placing a cannula into one of the large veins as it enters the
body’s trunk (most commonly the internal jugular, subclavian or
femoral veins) and advancing until the tip of the catheter sits in
the superior vena cava, or the iliac vein in the case of the femoral
catheter. Peripheral cannulae are placed in a limb or (rarely) the
scalp;
• Intraosseous access involves the insertion of a needle into
the bone marrow (usually in the tibia or the humerus, or less
commonly in the pelvis or sternum) to which an infusion line is
connected. It is often used in patients for whom intravenous
access is difficult to achieve, such as those with collapsed
peripheral veins and young children. Intraosseous needles can be
inserted manually, although the use of mechanical insertion
devices, such as the BIG Bone Injection Gun® and Arrow® EZ-
IO® Intraosseous Vascular Access System, have become
common. A pressurised fluid bag is required to ensure that the
fluid runs;
• Subcutaneous access involves the insertion of a needle or
catheter into the subcutaneous tissue that lies beneath the dermis
and epidermis layers. Hyaluronidase may be given to improve
absorption of infused substances into the circulation. Common
sites for subcutaneous infusion are the abdomen, thigh and
upper arm;
• Intraperitoneal access involves placing a catheter through
the abdominal wall and the delivery of fluids into the peritoneal
cavity, in similarity with peritoneal dialysis. This approach has
been used in resource poor settings to resuscitate children with
severe diarrhoea due to cholera infection (Mahalanabis 1970).
The intravenous route is the most commonly used method for
administering fluids (Waitt 2004). However, securing intravenous
access can be technically difficult in sick and dehydrated patients
and is likely to be particularly challenging for healthcare workers
obliged to wear personal protective equipment (PPE). Staff short-
ages and limitation of time spent at the bedside due to the chal-
lenge of wearing PPE for long periods in a hot environment may
also frustrate efforts to achieve intravenous access in large num-
bers of sick patients (Fowler 2014). Securing parenteral access may
also present risks to healthcare workers, e.g. needlestick injury or
inadvertent contact with body fluids associated with insertion or
dislodgement of parenteral access. For these reasons, an under-
standing of the relative merits of alternative routes (intravenous,
intraosseous, subcutaneous or intraperitoneal) for achieving par-
enteral access could be important for the management of patients
with EVD. The different approaches are likely to vary in terms of
ease of insertion and effectiveness for fluid replacement.
Why it is important to do this review
Due to the large number of cases and resource constraints, it is es-
sential that parenteral access in patients with EVD can be achieved
quickly and maintained with minimal clinical intervention. We
have therefore conducted a systematic review of randomised con-
trolled trials comparing alternative routes for achieving parenteral
access to assess their effectiveness and safety in terms of ease of
insertion and effectiveness for fluid replacement.
This Cochrane review has been prompted by the ongoing EVD
crisis in West Africa and the need to identify ways to improve the
medical care of those affected. However, we have not limited the
inclusion criteria to patients with EVD as we anticipated that it
was unlikely that we would find any trial research conducted in
this specific patient group. We believe that evidence derived from
trials involving patients who require insertion of parenteral access
for other indications is relevant to the management of patients
with EVD, as well as to the wider range of patients who require
parenteral infusions.
O B J E C T I V E S
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To compare the reliability, ease of use and speed of insertion of
different parenteral access methods.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials.
Eligible trials were those judged to have assigned participants us-
ing a method of random allocation (e.g. computer-generated ran-
domisation, random numbers table or drawing lots) or a quasi-
randommethod of allocation (e.g. alternation, date of birth or case
record number) (definition adapted from Box 6.3.a in Lefebvre
2011).
Types of participants
People of any age in whom insertion of a parenteral access method
is attempted for the purpose of infusing fluids or medication.
Trials involving the insertion of parenteral access under simulated
conditions, such as using manikins or cadavers in which healthcare
workers are randomly allocated to insert different parenteral access
methods, were also eligible.
Types of interventions
We considered the following parenteral access methods: intra-
venous (central venous access and peripheral venous access), in-
traperitoneal, subcutaneous and intraosseous (using both manual
and mechanical methods). We planned to explore the effects of
central venous access and peripheral venous access separately.
Only trials comparing two or more of the above parenteral routes
were eligible.
Types of outcome measures
Primary outcomes
• Success of route placement (’success’/’failure’ as defined in
the individual trial).
Secondary outcomes
• Time to infusion/placement.
• Average number of insertion attempts.
• Dislodgement of device during infusion.
• Time period with functional access.
• Local site reactions (e.g. infusion site pain, swelling,
infection).
• Clinician’s perception of ease of administration.
• Needlestick injury to healthcare workers.
• Patient’s discomfort.
• Mortality.
For trials assessing parenteral routes for fluid administration, we
extracted data on the following outcomes:
• Volume of fluid infused.
• Electrolyte levels and renal function (changes in serum
sodium, potassium, urea and creatinine).
Search methods for identification of studies
In order to reduce publication and retrieval bias we did not restrict
our search by language, date or publication status.
Electronic searches
We searched the following databases:
1. Cochrane Injuries Group Specialised Register (17
November 2014);
2. Cochrane Central Register of Controlled Trials
(CENTRAL, The Cochrane Library) (issue 10 of 12, 2014);
3. Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process &
Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid OLDMEDLINE(R) (1946 to 17 November 2014);
4. Embase Classic + Embase (OvidSP) (1947 to 17 November
2014);
5. CINAHL Plus (EBSCO) (1937 to 17 November 2014);
6. Clinicaltrials.gov (www.clinicaltrials.gov) (accessed 17
November 2014).
We adapted theMEDLINE search strategy (Appendix 1) as neces-
sary for each of the other databases: the added study filter is amod-
ified version of the Ovid MEDLINE(R) Cochrane Highly Sen-
sitive Search Strategy for identifying randomised trials (Lefebvre
2011). For the Embase search strategy we added the study design
terms used by the UK Cochrane Centre (Lefebvre 2011).
Searching other resources
We screened the reference lists of the eligible trials and review
articles for further potentially eligible studies. We also searched
the internet using the Google search engine (www.google.com)
with selected terms from the search strategy to identify further
unpublished or grey literature.
Data collection and analysis
Selection of studies
Two review authors (KK and DB, IR or HS) independently exam-
ined the records identified from the search and screened them by
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reviewing the title and abstract. We obtained the full texts of po-
tentially eligible studies and two review authors assessed whether
each study met the inclusion criteria. We resolved disagreements
through discussion or by asking a third review author (IR).
Data extraction and management
Two review authors (KK and GT) independently extracted data
using a data extraction form designed specifically for the review.
We extracted data on the following:
• patient characteristics (including age, sex, indication for
parenteral access);
• intervention characteristics (including description of
parenteral routes, use of PPE);
• trial methods (specifically information for ’Risk of bias’
assessment);
• outcome data.
We resolved any disagreements about the extracted data by discus-
sion or by asking a third review author (IR).
Assessment of risk of bias in included studies
Two review authors (KK and GT) assessed the risk of bias in the
included trials using The Cochrane Collaboration’s ’Risk of bias’
tool, as described by Higgins 2011a. We assessed the following
domains for each trial: sequence generation, allocation conceal-
ment, blinding (participants, personnel and outcome assessment),
incomplete outcome data and selective outcome reporting. We
completed a ’Risk of bias’ table, incorporating a description of the
trial against each of the domains and a judgement of the risk of
bias, as follows: ’low risk’, ’high risk’ or ’unclear risk’ of bias.
For the ’blinding of outcome assessment’ and ’incomplete outcome
data’ domains, we assessed the risk of bias by outcome group as
follows.
• Outcomes related to parenteral route insertion (success of
route placement; number of insertion attempts; dislodgement of
device during infusion; time period with functional access).
• Clinical outcomes (sodium; potassium; urea; creatinine;
mortality).
• Subjective outcomes (local site reactions, complications;
clinician’s perception of ease of administration; volume of fluid
infused; needlestick injury to healthcare workers; patient’s
discomfort).
Measures of treatment effect
For binary outcome data, we calculated risk ratios and 95% con-
fidence intervals (CI) and for continuous outcome data we calcu-
lated the mean difference and 95% CI for each trial. In a num-
ber of trials, summary continuous data were presented as medians
and ranges; in these cases, for the purpose of meta-analysis, we
estimated the corresponding means and standard deviations using
the method described in Hozo 2005 (Appendix 2).
Unit of analysis issues
For cross-over trials, we extracted effect estimates from an appro-
priate paired analysis from the trial reports or we calculated these
where possible. We included these estimates in the meta-analysis
using the generic inverse variancemethod. However, if a cross-over
trial presented data according to the treatment group, we analysed
the results from both periods of the cross-over trial as if they had
originated from a parallel design. This latter approach leads to a
unit of analysis error, causing the CIs to be too wide and the trial
to receive too little weight. However, we think that the resulting
conservative estimates are preferable to omitting all such data from
the analyses.
Cluster-randomised controlled trials that reported effect estimates
and confidence intervals derived from an appropriate analysis (e.g.
generalised estimating equations or multi-level modelling) would
have been included in the meta-analysis using the generic inverse
variance method. Alternatively, if any such trial had analysed data
at the level of the participant rather than at the cluster level, we
would have attempted an approximate analysis as described in
Higgins 2011b, assuming an estimate of the intracluster correla-
tion coefficient was available.
For trials involving multiple intervention groups, we followed the
approach described in Higgins 2011b. Where there were multiple
groups receiving the same parenteral access method, we combined
these to create a single pair-wise comparisonwith a group receiving
an alternative parenteral method.
Dealing with missing data
We analysed trial results on an intention-to-treat basis where the
necessary data were available. Where data in the trial reports were
not presented on an intention-to-treat basis but information about
exclusions was presented, we ’re-included’ exclusions to allow for
inclusion in themeta-analysis as intention-to-treat. Otherwise, we
used the data available from the trial report and conducted an
available-case analysis.
Assessment of heterogeneity
We assessed trial characteristics in terms of participants, interven-
tions and outcomes for clinical heterogeneity.
We examined statistical heterogeneity by visual inspection of for-
est plots, and by using the I² statistic and the Chi² test. The I²
statistic describes the percentage of total variation across studies
due to heterogeneity rather than chance. A value of 0% indicates
no observed heterogeneity and larger values show increasing het-
erogeneity; substantial heterogeneity is considered to exist when
I² is greater than 50% (Deeks 2011). For the Chi² test, we used
a P value of less than 0.10 to indicate the presence of statistically
significant heterogeneity.
We anticipated that differences in the definition of the primary
outcome, ’success’/’failure’ of insertion, between individual trials
might be a potential source of heterogeneity.
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Assessment of reporting biases
We planned to investigate the presence of reporting (publication)
bias using funnel plots if there were at least 10 trials for the same
outcome in the analysis.
Data synthesis
Where we judged the included trials to be too clinically heteroge-
neous to pool, we described the results narratively. When we con-
sidered a pooled analysis to be appropriate, we combined effect es-
timates using the fixed-effect model (also known as the weighted-
average method). We consider this approach to be preferable to
the random-effects model, which can give too much weight to
smaller trials that are often of poorer methodological quality.
Required sample size
Using TSA - Trial Sequential Analysis 0.9 Beta software, we esti-
mated that a total sample size of 1388 would be required for the
meta-analysis of our primary outcome to detect an intervention
effect reliably. This estimate is based on an assumed baseline event
rate of 50%, with 90% power to detect a clinically relevant differ-
ence of 20% at the 5% significance level, adjusted for heterogene-
ity anticipated at I² = 25%.
Subgroup analysis and investigation of heterogeneity
We conducted subgroup analyses to examine whether the effects
of the parenteral route of fluid administration varied by age of
patient (child versus adult) and use of PPE (PPE versus no PPE),
assuming that there was at least one trial in each subgroup.
Sensitivity analysis
We conducted sensitivity analyses to quantify the effects when
restricted to trials with adequate allocation concealment, assuming
that there was at least one trial contributing data to the analysis.
Summary of findings
We have also included the results of the review for the following
outcomes in ’Summary of findings’ tables. We included informa-
tion about the following outcomes:
• success of route placement;
• time to placement/start to infusion;
• dislodgement of device during infusion;
• volume of fluid infused;
• needlestick injuries.
We used GRADEpro 2014 to prepare the tables. We judged the
overall quality of the evidence for each outcome as ’high’, ’mod-
erate’, ’low’ or ’very low’ according to the GRADE approach
(Schünemann 2011). We considered the following:
• impact of the risk of bias of individual trials;
• precision of the pooled estimate;
• inconsistency or heterogeneity (clinical, methodological
and statistical);
• indirectness of evidence;
• impact of selective reporting and publication bias on effect
estimate.
R E S U L T S
Description of studies
Results of the search
The trial selection process is summarised in Figure 1. The com-
bined search strategy identified 1276 records, of which we judged
36 to be potentially eligible and obtained the full texts. After a full-
text review, we included 17 trials in the review, which involved 21
eligible pair-wise comparisons.
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Figure 1. Study flow diagram.
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Included studies
Full details of each trial are presented in the Characteristics of
included studies table; a summary is given below.
Design
Ten trials were randomised, parallel-group trials and seven were
randomised, cross-over trials.
Of the seven cross-over trials, five involved a two-period compar-
ison, one a four-period comparison and one a three-period com-
parison.
Sample sizes
The 17 trials included a combined total of 885 participants, of
whom 847 were patients requiring parenteral access and 38 were
health personnel who were attempting parenteral access under
simulated conditions. The median sample size was 37 (range 6
to 182). One hundred and five participants were included in the
cross-over trials and therefore acted as their own control.
Setting and participants
One trial was multicentre, conducted in 11 European countries.
The remaining trials were conducted in Denmark (n = 1), France
(n = 5), Germany (n = 1), India (n = 1), Spain (n = 1), Sweden (n
= 1), the USA (n = 3) and the UK (n = 3).
None of the included trials involved patients with Ebola virus dis-
ease (EVD) or were conducted in the context of a similar medi-
cal emergency. Instead, the included trials were conducted in the
following clinical settings: two involved the treatment of children
with dehydration in hospital; one involved patients receiving a
bone marrow transplant; six involved hospitalised elderly patients
requiring parenteral fluids to maintain or restore hydration; three
involved the infusion of insulin in patients with diabetes; one in-
volved patients with multifocal neuropathy being treated with im-
munoglobulin; one involved patients with malignant disease in an
oncology department; one involved paramedics attending out-of-
hospital cardiac arrests; one involved paramedic trainees attempt-
ing parenteral access on cadavers in a hospital training laboratory;
and one involved doctors and nurses attempting parenteral access
on manikins in a pre-hospital department.
Fifteen trials compared different parenteral routes in patients; 14
involved adults and one involved children (Banerjee 1994). The
other two studies by Lamhaut et al and Hubble 2001 used a cross-
over design to assign medical personnel to attempt different par-
enteral routes. Training manikins were used in Lamhaut and ca-
davers in Hubble 2001.
The purpose of the parenteral access was for the infusion of flu-
ids in 11 trials (Banerjee 1994; Challiner 1994; Dardaine 1995;
Delamaire 1992; Duems Noriega 2014; Hubble 2001; Lamhaut
2010 (noPPE); Lamhaut 2010 (with PPE);O’Keeffe1996;Reades
2011; Slesak 2003; Spandorfer 2005), and for the infusion ofmed-
ication (including insulin, bone marrow, immunoglobulin and
bleomycin) in six trials (Boullu-Sanchis 2006; Hägglund 1998;
Harbo 2009; Harvey 1987; Liebl 2009; Selam 1983).
Interventions
The included trials compared the following:
• Intravenous access versus intraosseous access, four trials
(Banerjee 1994; Hägglund 1998; Lamhaut 2010 (no PPE);
Lamhaut 2010 (with PPE); Reades 2011).
• Intravenous access versus subcutaneous access, 11 trials
(Boullu-Sanchis 2006; Challiner 1994; Dardaine 1995;
Delamaire 1992; Duems Noriega 2014; Harbo 2009; Harvey
1987; O’Keeffe 1996; Selam 1983; Slesak 2003; Spandorfer
2005).
• Intravenous access versus intraperitoneal access, one trial
(Selam 1983).
• Saphenous vein cutdown versus intraosseous access, one
trial (Hubble 2001).
• Intraperitoneal access versus subcutaneous access, one trial
(Selam 1983).
All of the trials assessing the intravenous method involved periph-
eral intravenous access.
One cross-over trial by Lamhaut et al compared intravenous and
intraosseous insertion with and without the wearing of PPE. For
the purpose of the meta-analysis, we considered separately the
data for the comparison of intravenous and intraosseous insertion
without PPE (Lamhaut 2010 (no PPE)) and with PPE (Lamhaut
2010 (with PPE)).
The trial by Reades et al compared intravenous access with two
intraosseous groups; one involved insertion into the humerus and
the other into the tibia (Reades 2011). For the purpose of the
meta-analysis, we combined the data from the two intraosseous
groups to derive a single comparison with the intravenous group.
The cross-over trial by Selam et al compared three parenteral meth-
ods for administering insulin - intravenous, subcutaneous and in-
traperitoneal (Selam 1983). We considered separately the results
from the three single pair-wise comparisons (intravenous versus
subcutaneous, intravenous versus intraperitoneal, and subcuta-
neous versus intraperitoneal) in this review.
Outcomes
The trials reporting data on the outcomes of interest are as follows:
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• Success of route of insertion, six trials.
• Time to infusion/placement, four trials.
• Number of insertion attempts, one trial.
• Dislodgement of device during infusion, two trials.
• Time period with functional access, one trial.
• Local site reactions (e.g. erythema, oedema, swelling,
infection), 11 trials.
• Clinician’s perception of ease of administration, three trials.
• Needlestick injury to healthcare workers; no trials.
• Patient’s discomfort (pain or discomfort); five trials.
• Mortality, two trials.
• Volume of fluid infused, five trials.
• Serum sodium, two trials.
• Serum potassium, one trial.
• Urea, two trials.
• Creatinine, three trials.
Excluded studies
A list of excluded studies with the reasons for their exclusion is
presented in Characteristics of excluded studies.
Risk of bias in included studies
Our judgements regarding each ’Risk of bias’ item for each in-
cluded trial are presented in Figure 2.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
One trial alternately assigned patients into groups and we judged
it to be at high risk of bias (Banerjee 1994). Four trials used an ad-
equate method of sequence generation and we judged them to be
at low risk of bias; of these, one trial referred to a random numbers
table (O’Keeffe 1996), and three used computer-generated ran-
domisation (Challiner 1994; Lamhaut 2010 (no PPE); Lamhaut
2010 (with PPE); Spandorfer 2005). We rated the remaining 12
trials as unclear due to insufficient information (Boullu-Sanchis
2006; Dardaine 1995; Delamaire 1992; Duems Noriega 2014;
Hägglund 1998; Harbo 2009; Harvey 1987; Hubble 2001; Liebl
2009; Reades 2011; Selam 1983; Slesak 2003).
Allocation concealment
We judged allocation to have been inadequately concealed and at
high risk of bias in two trials (Banerjee 1994; Reades 2011). Two
trials used amethod of central allocation (Harbo 2009; Spandorfer
2005), and one trial used sequentially numbered, sealed envelopes
(Challiner 1994); we considered all three to be adequately con-
cealed and at low risk of bias. We rated the remaining 12 tri-
als as unclear due to insufficient information (Boullu-Sanchis
2006; Dardaine 1995; Delamaire 1992; Duems Noriega 2014;
Hägglund 1998; Harvey 1987; Hubble 2001; Lamhaut 2010 (no
PPE); Lamhaut 2010 (with PPE); Liebl 2009; O’Keeffe 1996;
Selam 1983; Slesak 2003).
Blinding
Blinding of participants and personnel
Due to the nature of the interventions under study, it was not
feasible for participants and personnel to be blinded to allocation
status and we judged all 17 trials to be at high risk of bias, although
it is unclear in which direction the results would have been biased.
Blinding of outcome assessment
Outcomes related to parenteral route insertion
We judged that measurement of these outcomes was likely to have
been influenced by lack of blinding so we judged all 10 trials
reportingdata on these outcomes to be at high risk of bias (Banerjee
1994; Challiner 1994; Dardaine 1995; Delamaire 1992; Duems
Noriega 2014; Hubble 2001; Lamhaut 2010 (no PPE); Lamhaut
2010 (with PPE); Reades 2011; Slesak 2003; Spandorfer 2005).
Clinical outcomes
We judged that measurement of these outcomes was not likely to
have been influenced by lack of blinding so we judged all four trials
reporting data on these outcomes to be at low risk of bias (Banerjee
1994; Challiner 1994; Duems Noriega 2014; Slesak 2003).
Subjective outcomes
We judged that measurement of these outcomes was likely to
have been influenced by lack of blinding so we judged all 13 tri-
als reporting data on these outcomes to be at high risk of bias
(Boullu-Sanchis 2006; Challiner 1994; Delamaire 1992; Duems
Noriega 2014; Hägglund 1998; Harbo 2009; Harvey 1987; Liebl
2009; O’Keeffe 1996; Reades 2011; Selam 1983; Slesak 2003;
Spandorfer 2005).
Incomplete outcome data
Outcomes related to parenteral route insertion
Of the 11 trials reporting data on one or more of these out-
comes, we judged three to be at high risk of bias (Banerjee 1994;
Challiner 1994; Duems Noriega 2014), and eight at low risk of
bias (Dardaine 1995; Delamaire 1992; Hubble 2001; Lamhaut
2010 (no PPE); Lamhaut 2010 (with PPE); Reades 2011; Slesak
2003; Spandorfer 2005).
Clinical outcomes
Of the six trials reporting data on one or more of these outcomes,
we judged three to be at high risk of bias (Banerjee 1994; Duems
Noriega 2014; O’Keeffe 1996), and three at low risk of bias (
Challiner 1994; Reades 2011; Slesak 2003).
Subjective outcomes
Of the 13 trials reporting data on one or more of these outcomes,
we judged four to be at high risk of bias (Duems Noriega 2014;
Hägglund 1998; Liebl 2009; O’Keeffe 1996) , and nine at low risk
of bias (Boullu-Sanchis 2006; Challiner 1994; Delamaire 1992;
Harbo 2009; Hubble 2001; Reades 2011; Selam 1983; Slesak
2003; Spandorfer 2005).
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Selective reporting
We found clinical trial registration records for two trials, both of
which had been registered after the start of recruitment. For one
of these trials, outcomes not mentioned in the registration record
were reported within the final report so we judged this trial to be at
high risk of bias (Reades 2011). Therewere no apparent differences
in the specified outcomes for the second trial, which we judged
to be at unclear risk of bias due to the retrospective registration
(Harbo 2009). We also judged the risk of bias for the remaining
15 trials to be unclear as we had insufficient information to permit
judgement.
Effects of interventions
See: Summary of findings for themain comparison Intravenous
versus intraosseous route for achieving parenteral access;
Summary offindings 2 Intravenous versus subcutaneous route for
achieving parenteral access; Summary of findings 3 Saphenous
vein cutdown versus intraosseous route for achieving parenteral
access
Peripheral intravenous versus intraosseus access
We have presented separately two effect estimates from one four-
period cross-over trial in the analyses but have not combined these
with data from parallel-group trials (Lamhaut 2010 (no PPE);
Lamhaut 2010 (with PPE)).
Insertion failures
Insertion failures were reported by three trials (Banerjee 1994;
Lamhaut 2010 (no PPE); Lamhaut 2010 (with PPE); Reades
2011). The data fromLamhaut 2010 (no PPE) and Lamhaut 2010
(with PPE) originated from the same cross-over trial, therefore
we did not pool these data in the meta-analysis. Furthermore,
as there were no failures in either Lamhaut 2010 (no PPE) or
Lamhaut 2010 (with PPE) treatment effects for these comparisons
could not be estimated. The pooled estimate is therefore based
on data from Banerjee 1994 and Reades 2011. More patients in
the intravenous group experienced an insertion failure than in the
intraosseous group (risk ratio (RR) 3.89, 95% confidence interval
(CI) 2.39 to 6.33; n = 242; P value < 0.0001) (Analysis 1.1). There
was moderate statistical heterogeneity between trials (I² = 48%),
however it was not statistically significant (Chi² P value = 0.16)
and the direction of the effect estimates was consistent.
We rated the quality of the evidence as low according to GRADE,
as we downgraded it for risk of bias and imprecision (Summary of
findings for the main comparison).
Subgroup analysis
There was no evidence of a difference in effect according to the
age of participants. The risk of insertion failure was higher in the
intravenous group in both the one trial involving adults (RR 3.24,
95% CI 2.00 to 5.27; n = 182; P value < 0.0001) (Reades 2011),
and the one trial involving children (RR 21.00, 95% CI 1.29 to
342.93; n = 60; P value = 0.03) (Banerjee 1994) (test for subgroup
differences: Chi² = 1.67, df = 1 (P value = 0.20), I² = 40.1%)
(Analysis 1.2).
Time to infusion/placement
Time to infusion/placement was reported by three trials (Banerjee
1994; Lamhaut 2010 (no PPE); Lamhaut 2010 (with PPE);
Reades 2011). Due to clinical heterogeneity we did not calculate
a pooled estimate, although effect estimates from each trial are
presented on a forest plot to provide a visual summary. It took
longer to achieve intravenous access than intraosseous access in all
trials, with the difference reaching statistical significance in two
trials but not in the third (Analysis 1.3).
In Reades 2011, the data for the humerus intraosseous and tibia
intraosseous groups were combined for the analysis, although we
note that there was a difference in the average time taken for
insertion between the sites: mean ± standard deviation (SD) for
humeral insertion = 420 seconds ± 91.50 and for tibial insertion
= 276 seconds ± 39.75.
We rated the quality of the evidence as moderate according to
GRADE, aswe downgraded it for risk of bias (Summary of findings
for the main comparison).
Average number of insertion attempts
The average number of insertion attemptswas reported by one trial
(Reades 2011). There was no difference between the two groups
(mean difference (MD) 0.00, 95% CI -0.07 to 0.07; n = 182; P
value = 1.00) (Analysis 1.4).
Dislodgement of device during infusion
Dislodgement of the device during infusion was reported by one
trial (Reades 2011). There were fewer dislodgements in the in-
travenous access group, although the difference is not statistically
significant (RR 0.53, 95% CI 0.18 to 1.55; n = 182; P value =
0.25) (Analysis 1.5). Most of the dislodgements (10/13) occurred
in the intraosseous patients who had the device inserted into the
proximal humerus.
We rated the quality of the evidence as low according to GRADE,
as we downgraded it for risk of bias and imprecision (Summary of
findings for the main comparison).
Time with functional access
None of the trials reported data on this outcome.
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Local site reactions
Infection
One trial, involving the infusionof bonemarrow, reportednumber
of patients who developed bacteraemia during the first month
(Hägglund 1998). There were fewer cases of bacteraemia in the
intravenous group, although the difference was not statistically
significant (RR 5.57, 95% CI 0.35 to 88.77; n = 28; P value =
0.22) (Analysis 1.6).
Clinician’s perception of administration of access route
One trial measured the paramedics’ perception of how comfort-
able they felt when administering each method to each patient
(Reades 2011). Paramedics were less likely to report that they were
uncomfortable when inserting via the intravenous route (RR 0.15,
95% CI 0.04 to 0.61; n = 182; P value = 0.008) (Analysis 1.7).
Needlestick injuries
None of the trials reported data on this outcome.
Patient discomfort
None of the trials reported data on this outcome.
Mortality
None of the trials reported data on this outcome.
Volume of fluid infused
The volume of fluid infused was reported by one trial (Reades
2011). A larger volume of fluid was infused via the intravenous
route than the intraosseous route (MD 400 ml, 95% CI 365.57
to 434.43; n = 182; P value < 0.0001) (Analysis 1.8).
We rated the quality of the evidence as moderate according to
GRADE, aswe downgraded it for risk of bias (Summary of findings
for the main comparison).
Electrolyte level
Electrolyte level was reported by one trial (Banerjee 1994). There
was no evidence of a difference in serum sodium (MD -1.00, 95%
CI -5.36 to 3.36; n = 60; P value = 0.65) or potassium (MD -0.40,
95% CI -2.97 to 2.17; n = 60; P value = 0.76) between groups
(Analysis 1.9).
Renal function
Renal function was reported by one trial (Banerjee 1994). The
average levels of both urea and creatinine were lower in the in-
travenous group; the difference was not statistically significant for
urea (MD -5.00, 95% CI -10.53 to 0.53; n = 60; P value = 0.08),
but it was statistically significant for creatinine (MD -35.00, 95%
CI -44.66 to -25.34; n = 60; P value < 0.0001) (Analysis 1.10).
Sensitivity analysis
Sensitivity analysis was not possible as we judged none of the trials
comparing intravenous and intraosseous access to be at low risk
of bias for allocation concealment.
Peripheral intravenous versus subcutaneous access
Insertion failures
Insertion failures were reported by three trials (Delamaire 1992;
O’Keeffe 1996; Spandorfer 2005). More patients in the intra-
venous group experienced an insertion failure than in the subcuta-
neous group (RR 14.79, 95%CI 2.87 to 76.08; n = 238) (Analysis
2.1). There was no statistical heterogeneity between trials (Chi² P
value = 0.50; I² = 0%).
We rated the quality of the evidence as moderate according to the
GRADE system, as we downgraded it for imprecision (Summary
of findings 2).
Sensitivity analysis
The effect remained when we restricted the analysis to the one
trial with adequate allocation concealment (Spandorfer 2005) (RR
32.13, 95% CI 1.96 to 525.87; n = 148; P value = 0.01) (Analysis
2.2).
Subgroup analysis
Two trials involved adults (Delamaire 1992; O’Keeffe 1996), and
one trial involved children (Spandorfer 2005). The effect estimates
for both subgroups were consistent, with an increased risk of inser-
tion failures in the intravenous group, although the effect was not
statistically significant for the subgroup of trials involving adults
(adults RR 6.00, 95% CI 0.76 to 47.39; n = 90; P value = 0.09
versus children RR 32.13, 95% CI 1.96 to 525.87; n = 148; P
value = 0.01). However, there is no evidence that the effect varied
between these subgroups (test for subgroup differences: Chi² =
0.90, df = 1 (P value = 0.34), I² = 0%).
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Time to infusion/placement
Time to placement/start of infusion was reported by two trials
(Slesak 2003; Spandorfer 2005). Insertion of the intravenous route
took longer than the subcutaneous route in both trials, however
a pooled estimate could not be calculated because of insufficient
data (i.e. no variance estimates) presented in Spandorfer 2005.
In Slesak 2003, it took on average twominutes longer (MD120.00
seconds, 95%CI -4.80 to 244.80; n = 96; P value = 0.06) to insert
via the intravenous route (Analysis 2.4). In Spandorfer 2005 (n
= 148), the median time from first insertion attempt to start of
infusion in the intravenous group was 11.8 minutes compared to
3.5 minutes in the subcutaneous group.
We rated the quality of the evidence as low according to GRADE,
as we downgraded it for risk of bias and imprecision (Summary of
findings 2).
Average number of insertion attempts
The average number of insertion attempts was not directly mea-
sured by any of the trials. However, O’Keeffe 1996 (n = 60) re-
ported that 41 cannulae were used in the intravenous group com-
pared to 34 in the subcutaneous group.
Dislodgement of device during infusion
One trial reported the number of dislodgements caused by patients
pulling out the device (Duems Noriega 2014). Patients in the
intravenous group were more likely to dislodge the device than
those in the subcutaneous group (RR 3.78, 95%CI 1.16 to 12.34;
n = 67; P value = 0.03) (Analysis 2.5).
We rated the quality of the evidence as low according to GRADE,
as we downgraded it for risk of bias and imprecision (Summary of
findings 2).
Time with functional access
One trial measured the length of time in days before each cannula
needed to be changed (Slesak 2003). There was no statistically
significant difference observed between groups (MD 0.80 days,
95% CI -0.05 to 1.65; n = 96; P value = 0.07) (Analysis 2.6).
Local site reactions
See Analysis 2.7 and Analysis 2.8.
Any
The occurence of any local site reactions was reported by five trials
(Boullu-Sanchis 2006; Challiner 1994; Harbo 2009; Selam 1983;
Spandorfer 2005). There were fewer local site reactions in the
intravenous group than in the subcutaneous group, although the
difference was not statistically significant (RR 0.91, 95% CI 0.80
to 1.02; n = 247). There was substantial statistical heterogeneity
between trials (Chi² P value < 0.0001; I² = 58%).
Sensitivity analysis
There was a statistically significant reduced risk associated with
the intravenous method when the analysis was restricted to the
three trials with adequate allocation concealment (Challiner 1994;
Harbo 2009; Spandorfer 2005) (RR 0.87, 95% CI 0.79 to 0.96; n
= 202). There was no evidence of statistical heterogeneity between
trials (Chi² P value = 0.30; I² = 17%).
Erythema
Erythema was reported by four trials (Challiner 1994; Harbo
2009; Slesak 2003; Spandorfer 2005). There were fewer cases of
erythema in the intravenous group than in the subcutaneous group
(RR 0.43, 95% CI 0.31 to 0.61; n = 296). There was substantial
statistical heterogeneity between trials (Chi² P value < 0.0001; I²
= 63%).
Sensitivity analysis
The effect remainedwhenwe restricted the analysis to the three tri-
als with adequate allocation concealment (Challiner 1994; Harbo
2009; Spandorfer 2005) (RR 0.33, 95%CI 0.22 to 0.49; n = 202).
There was no statistical heterogeneity between trials (Chi² P value
= 0.73; I² = 0%).
Swelling
Swelling was reported by one trial (Spandorfer 2005). There were
fewer cases of swelling in the intravenous group than in the sub-
cutaneous group (RR 0.26, 95% CI 0.17 to 0.41; n = 148).
Infection
Infection was reported by four trials (Delamaire 1992; Duems
Noriega 2014; Harbo 2009; Slesak 2003). More patients in the
intravenous group developed an infection (e.g. cellulitis and lym-
phangitis) compared to the subcutaneous group (RR 3.70, 95%
CI 1.06 to 12.88; n = 211; P value = 0.04). There was no statistical
heterogeneity between trials (Chi² P value = 0.37; I² = 6%).
Sensitivity analysis
There was no difference in the risk of infection between groups
when we restricted the analysis to the one trial with adequate
allocation concealment (Harbo 2009) (RR 3.00, 95% CI 0.14 to
65.16; n = 18; P value = 0.48).
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Oedema
Oedema was reported by seven trials (Challiner 1994; Delamaire
1992; Duems Noriega 2014; Harbo 2009; O’Keeffe 1996; Slesak
2003; Spandorfer 2005). Fewer patients in the intravenous group
experienced oedema at the insertion site compared to those in the
subcutaneous group (RR 0.42, 95% CI 0.25 to 0.72; n = 453;
P value = 0.001). There was no statistical heterogeneity between
trials (Chi² P value = 0.89; I² = 0%).
Sensitivity analysis
The effect was not statistically significant when we restricted the
analysis to the three trials with adequate allocation concealment
(Challiner 1994; Harbo 2009; Spandorfer 2005) (RR 0.25, 95%
CI 0.06 to 1.15; n = 202; P value = 0.07). There was no statistical
heterogeneity between trials (Chi² P value = 0.93; I² = 0%).
Phlebitis
Phlebitiswas reported by three trials (DuemsNoriega 2014;Harbo
2009; Slesak 2003). More patients in the intravenous group expe-
rienced phlebitis than in the subcutaneous group (RR 5.04, 95%
CI 1.14 to 22.30; n = 181). There was no statistical heterogeneity
between trials (Chi² P value = 0.93; I² = 0%).
Sensitivity analysis
The effect was not statistically significant when we restricted the
analysis to the one trial with adequate allocation concealment (
Harbo 2009) (RR 3.00, 95% CI 0.14 to 65.16; n = 18; P value =
0.48).
Clinician’s perception of ease of administration
Slesak 2003 measured doctors’ and nurses’ perceptions of the feasi-
bility of each insertion method using a Likert-like scale. There was
no difference between the perceived feasibility of the two methods
when scored by either the nurses (MD 0.00, 95% CI -0.12 to
0.12; n = 87; P value = 1.00) or doctors (MD 0.00, 95% CI -0.14
to 0.14; n = 96; P value = 1.00) (Analysis 2.9).
In Spandorfer 2005, clinicians were more likely to report that the
intravenous access was difficult to perform than the subcutaneous
access (RR 6.33, 95%CI 2.32 to 17.23; n = 148; P value = 0.0003)
(Analysis 2.10).
Needlestick injuries
None of the trials reported data on this outcome.
Patient discomfort
Pain
Three trials reported the number of patients with pain associ-
ated with the parenteral access method (Harbo 2009; Slesak 2003;
Spandorfer 2005). There is no evidence that the number of pa-
tients reporting pain differed between the intravenous and sub-
cutaneous groups (RR 1.01, 95% CI 0.83 to 1.22; n = 262; P
value = 0.94). There was no statistical heterogeneity between trials
(Chi² P value = 0.33; I² = 9%) (Analysis 2.11). We downgraded
the quality of the evidence to low, due to high risk of bias and
imprecision arising from small sample sizes.
Sensitivity analysis
The lack of evidence for a difference remained when we restricted
the analysis to the two trials with adequate allocation concealment
(Harbo 2009; Spandorfer 2005) (RR 0.97, 95% CI 0.81 to 1.16;
n = 166; P value = 0.77). There was evidence of statistical hetero-
geneity between trials (I² = 53%); however, it was not statistically
significant (Chi² P value = 0.15) (Analysis 2.12).
Discomfort
In Slesak 2003, patients were also asked to score the discomfort
of the procedure (1 = very good to 6 = very bad). There was no
difference in the patients’ scores between the two groups (MD
0.00, 95% CI -0.21 to 0.21; n = 54; P value = 1.00) (Analysis
2.13).
Agitation
Two trials reported the number of patients who were agitated
(Duems Noriega 2014; O’Keeffe 1996). Patients in the intra-
venous group were more likely to be agitated than those in the
subcutaneous group (RR 1.84, 95% CI 1.26 to 2.70; n = 125;
P value = 0.002). There was no statistical heterogeneity between
trials (Chi² P value = 0.34; I² = 0%).
Mortality
Mortality was reported by two trials (Challiner 1994; Duems
Noriega 2014). InChalliner 1994, one patient in the subcutaneous
group died on day two and inDuemsNoriega 2014, three patients
(two in the intravenous group, one in the subcutaneous group)
died in the first 72 hours. When we pooled the data there was no
difference in the risk of death between groups (RR 1.04, 95% CI
0.18 to 5.92; n = 103; P value = 0.96). There was no statistical
heterogeneity between trials (Chi² P value = 0.40; I² = 0%) (
Analysis 2.14).
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Sensitivity analysis
The lack of evidence for a difference in risk remained when we
restricted the analysis to the one trial with adequate allocation
concealment (Challiner 1994) (RR 0.37, 95% CI 0.02 to 8.53; n
= 36; P value = 0.53) (Analysis 2.15).
Volume of fluid infused
The volume of fluid infused was reported by four trials (Duems
Noriega 2014; O’Keeffe 1996; Slesak 2003; Spandorfer 2005).
Due to clinical heterogeneity we did not calculate a pooled esti-
mate, although effect estimates from each trial are presented on a
forest plot to provide a visual summary (Analysis 2.16). A larger
volume of fluid was infused via the intravenous route in all but
one trial.
We rated the quality of the evidence as low according to GRADE,
as we downgraded it for risk of bias and inconsistency (Summary
of findings 2).
Sensitivity analysis
There was no difference in the volume of fluid infused in the
one trial with adequate allocation concealment (Spandorfer 2005)
(MD 90.80 95% CI -63.55 to 245.15; n = 148; P value = 0.25).
Electrolyte levels
Sodium
Sodium level was reported by one trial (Slesak 2003). The mean
sodium level was higher in the intravenous group (139 ± 5mmol/l)
compared to the subcutaneous group (137 ± 5 mmol/l), although
the difference is not statistically significant (MD -2.00 mmol/l,
95% -0.24 to 4.24; n = 77; P value = 0.08) (Analysis 2.18).
Potassium
None of the trials reported data on this outcome.
Renal function
See Analysis 2.19.
Urea
Urea level was reported by one trial (Duems Noriega 2014). Urea
levels were on average lower in the intravenous group than in the
subcutaneous group, although the difference is not statistically
significant (MD -11.29 mg/dL, 95% CI -24.69 to 2.11; n = 67;
P value = 0.10).
Creatinine
Creatinine level was reported by two trials (Duems Noriega 2014;
Slesak 2003). There was no difference in creatinine levels between
the two groups (MD -0.08, 95% CI -0.33 to 0.16; n = 138; P
value = 0.51). There was no statistical heterogeneity between trials
(Chi² P value = 0.95; I² = 0%).
Saphenous vein cutdown versus intraosseous access
This comparison was assessed by one cross-over trial (n = 13)
(Hubble 2001).
Insertion failures
There were more failures when attempting saphenous vein cut-
down than intraosseous access, although the difference was not
statistically significant (RR 4.00, 95% CI 0.51 to 31.13; P value
= 0.19) (Analysis 3.1).
We rated the quality of the evidence as low according to GRADE,
as we downgraded it for risk of bias and imprecision (Summary of
findings 3).
Time to infusion/placement
On average it took about 3.5 minutes longer to achieve access by
saphenous vein cutdown than intraosseous access (MD 219.60
seconds, 95% CI 135.44 to 303.76; P value < 0.0001) (Analysis
3.2).
We rated the quality of the evidence as moderate according to
GRADE, aswe downgraded it for risk of bias (Summary of findings
3).
Average number of insertion attempts
The trial did not report data on this outcome.
Dislodgement of device during infusion
The trial did not report data on this outcome.
Time with functional access
This outcome was not relevant, as insertion attempts were on a
cadaver.
Local site reactions
This outcome was not relevant, as both insertion attempts were
on a cadaver.
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Clinician’s perception of ease/feasibility of access route
The trial did not report data on this outcome.
Needlestick injuries
The trial did not report data on this outcome.
Patient discomfort
This outcome was not relevant, as insertion attempts were on a
cadaver.
Mortality
This outcome was not relevant, as insertion attempts were on a
cadaver.
Volume of fluid infused
This outcome was not relevant, as insertion attempts were on a
cadaver.
Electrolyte levels
This outcome was not relevant, as insertion attempts were on a
cadaver.
Renal function
This outcome was not relevant, as insertion attempts were on a
cadaver.
Peripheral intravenous versus intraperitoneal access
This comparison was assessed by one cross-over trial (n = 6) (Selam
1983), which compared intravenous and intraperitoneal access for
insulin infusion.
Insertion failures
The trial did not report data on this outcome.
Time to infusion/placement
The trial did not report data on this outcome.
Average number of insertion attempts
The trial did not report data on this outcome.
Dislodgement of device during infusion
The trial did not report data on this outcome.
Time with functional access
The trial did not report data on this outcome.
Local site reactions
One of the six patients suffered an obstructed catheter during the
intravenous phase. No complications data were reported for the
intraperitoneal group.
Clinician’s perception of ease of administration
The trial did not report data on this outcome.
Needlestick injuries
The trial did not report data on this outcome.
Patient discomfort
Two of six patients suffered transient episodes of abdominal pain
during the intraperitoneal phase. No pain data were reported for
the intravenous group.
Mortality
The trial did not report data on this outcome.
Volume of fluid infused
This outcome was not relevant, as both trials involved the infusion
of medication, not fluids for hydration.
Electrolyte levels
This outcome was not relevant, as both trials involved the infusion
of medication, not fluids for hydration.
Renal function
This outcome was not relevant, as both trials involved the infusion
of medication, not fluids for hydration.
Intraperitoneal versus subcutaneous access
Two cross-over trials compared the intraperitoneal and subcuta-
neous routes for infusionofmedications (Liebl 2009; Selam1983).
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Insertion failures
The trials did not report data on this outcome.
Time to infusion/placement
The trials did not report data on this outcome.
Average number of insertion attempts
The trials did not report data on this outcome.
Dislodgement of device during infusion
The trials did not report data on this outcome.
Time with functional access
The trials did not report data on this outcome.
Local site reactions
In Selam 1983, all six patients experienced local reactions after
three to four weeks of the subcutaneous phase, beginning with
induration and inflammation at the insertion site before rejection
of the catheter.
In Liebl 2009, it is reported that 21% of patients in months one
to six and 10% patients in months seven to 12 experienced local
inflammation or infection during the intraperitoneal phase. The
number of complications during the subcutaneous phase was not
reported.
Clinician’s perception of ease of administration
The trials did not report data on this outcome.
Needlestick injuries
The trials did not report data on this outcome.
Patient discomfort
In Selam 1983, two of the six patients suffered transient episodes
of abdominal pain during the intraperitoneal phase.
In Liebl 2009, it is reported that 12% of patients in months one
to six and 49% in months seven to 12 reported severe pain during
the intraperitoneal phase.
Mortality
The trials did not report data on this outcome.
Volume of fluid infused
This outcome was not relevant, as both trials involved the infusion
of medication not fluids for hydration.
Electrolyte levels
This outcome was not relevant, as both trials involved the infusion
of medication not fluids for hydration.
Renal function
This outcome was not relevant, as both trials involved the infusion
of medication not fluids for hydration.
Reporting bias
There were insufficient data to produce funnel plots for any of the
outcomes.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Intravenous versus subcutaneous route for achieving parenteral access
Patient or population: adults or children requiring parenteral access for infusion of fluids or medication
Settings: USA (children’s unit) and Europe (older people care units)
Intervention: intravenous route
Comparison: subcutaneous route
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Subcutaneous route Intravenous route
Insertion failures Study population RR 14.79
(2.87 to 76.08)
238
(3 RCTs)
⊕⊕⊕©
MODERATE 1,2
IV rate calculated based
on an assumed rate with
the subcutaneous route
generated from correc-
tion for zero events (1.14
per 100)
There were no insertion
failures observed with the
subcutaneous route in the
studies
17 per 100
(3 to 76)
Time to infusion/place-
ment
The mean time to place-
ment/start of infusion in
the subcutaneous group
was 300 seconds
The mean time to place-
ment/start of infusion in
the IV groupwas 120 sec-
onds longer (4.8 shorter
to 244.8 longer)
- 96
(1 RCT)
⊕⊕©©
LOW 3,4
-
Dislodgement of device Study population RR 3.78
(1.16 to 12.34)
67
(1 RCT)
⊕⊕©©
LOW 3,4
-
9 per 100 34 per 100
(10 to 100)
Needlestick injuries No studies reported this
outcome
No studies reported this
outcome
- NA NA -
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Volume of fluid infused There was variation in the amount of fluid adminis-
tered between trials, therefore we did not pool data.
The size and direction of the effects differed across
the 4 studies reporting data for this outcome
- (4 RCTs) ⊕⊕©©
LOW 3,5
-
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; IV: intravenous; NA: not applicable; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded one level for imprecision: estimate is statistically significant at the 5% level (P value <0.001); however, the estimated
required information size has not been achieved and we cannot discount the possibility that it is a false positive. Downgraded one
level for risk of bias: estimates based on trials at unclear and/or high risk of bias for ≥ 1 domain.
2Not downgraded for risk of bias as effect remained when analysis was restricted to adequately concealed trials.
3Downgraded one level for risk of bias: estimate based on trial(s) at unclear and/or high risk of bias for ≥ 1 domain.
4Downgraded one level for imprecision: effect borderline or not statistically significant at the 5% level and/or wide CI.
5Downgraded one level for inconsistency: variation in both magnitude (I² >50%) and direction of effects.
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Saphenous vein cutdown versus intraosseous route for achieving parenteral access
Patient or population: trainee paramedics using both methods of gaining parenteral access on cadavers
Settings: USA (training laboratory)
Intervention: saphenous vein cutdown
Comparison: intraosseous
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Intraosseous Saphenous vein cut-
down
Insertion failures Study population RR 4
(0.51 to 31.13)
13
(1 RCT)
⊕⊕©©
LOW 1,2
-
77 per 1000 308 per 1000
(39 to 2395)
Time to infusion/place-
ment
Analysed as generic inverse variance outcome type.
Difference betweenmeanswas 219.6 seconds longer
with saphenous vein cutdown (155.09 longer to 284.
11 longer)
- 13
(1 RCT)
⊕⊕⊕©
MODERATE 1
-
Dislodgement of device No studies reported this
outcome
No studies reported this
outcome
- NA NA -
Needlestick injuries No studies reported this
outcome
No studies reported this
outcome
- NA NA -
Volume of fluid inserted No studies reported this
outcome
No studies reported this
outcome
- NA NA -
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; NA: not applicable; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded one level due to risk of bias: estimate based on trial at high or unclear risk of bias for all domains.
2Downgraded one level for imprecision: estimate based on few events and wide CI that includes both appreciable increase and decrease
in risk
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D I S C U S S I O N
Summary of main results
Evidence from randomised controlled trials suggests that in-
traosseous access may be achievedmore rapidly and with fewer in-
sertion failures than intravenous access. Subcutaneous access is also
associated with fewer insertion failures than intravenous access.
Taken together the evidence suggests that intraosseous and sub-
cutaneous access are viable alternatives to peripheral intravenous
access when the latter cannot be achieved. However, when inserted
successfully, more fluid can be infused by the intravenous route
than by either the intraosseous or subcutaneous route.
Only one small trial involving insertion of parenteral access into
manikins explored the effect of personal protective equipment
(PPE), thus there is insufficient evidence to determine reliably
whether or not the use of PPE impacts on the merits of the dif-
ferent approaches. Also, there is insufficient evidence to draw any
inferences about the relative merits of intraperitoneal access com-
pared to other methods and there are no trials involving central
intravenous access.
A particularly important consideration in the context of patients
with Ebola virus disease (EVD) may be the likelihood of dislodge-
ment of the parenteral access device during use. Two trials, one
comparing intravenous with intraosseous access and one compar-
ing intravenous with subcutaneous access, recorded the number
of dislodgements. However, both were inadequately powered and
were at risk of bias for important quality domains. They therefore
do not provide reliable evidence on this important outcome so we
are unable to draw any firm conclusions. There are also insufficient
data to determine whether the intravenous route is associated with
an increased or decreased risk of adverse events when compared
to intraosseous access. When compared to subcutaneous access,
intravenous access appears to cause less erythema, but more in-
fection and phlebitis. However, the difference between the two
methods in the risk of infection and phlebitis was not statistically
significant when we restricted these analyses to trials with ade-
quate allocation concealment. As expected given the nature of the
insertion, subcutaneous infusion was associated with an increased
risk of oedema and swelling.
Overall completeness and applicability of
evidence
The included trials were conducted in a variety of clinical contexts
involving a broad range of patient groups. Despite this we judged
them tobe sufficiently clinically homogenous to allowpooled anal-
yses for most outcomes. As we anticipated at the protocol stage,
none of the included trials were conducted in the context of EVD
or a similar medical emergency.However, we judge that the advan-
tages and disadvantages of the different parenteral methods ob-
served in other clinical settings are likely to be similar in the con-
text of EVD. If a trial, or ameta-analysis of all relevant trials, shows
that a particular intervention increases or decreases the probability
of a given outcome in one group of patients, we have to consider
what effect it might have in another group of patients. Some peo-
ple believe that an intervention should only be used in patients
similar to those included in the trial (or trials) that showed the
intervention to be effective. We believe that this view is naive. To
generalise trial results properly we have to consider themechanism
by which the intervention affected the outcome and the factors
that might be relevant to this mechanism. The results of this sys-
tematic review suggest that insertion of intraosseous access may be
less likely to fail and may be quicker than the intravenous method.
Would this also be the case in patients with EVD? Patients with
EVD are often severely dehydrated due to severe gastrointestinal
fluid losses. In such patients, we might reasonably expect that se-
curing intravenous access would be even more difficult. Health-
care workers treating patients with EVD must wear personal pro-
tective equipment and often wear two or even three layered pairs
of protective gloves. This would be expected to reduce their ability
to palpate a vein, which would again make securing intravenous
access more difficult. On the other hand, dehydration and health
worker dexterity are less important for intraosseous access. For this
reason, we would expect that securing intraosseous access would
usually be quicker and easier than securing intravenous access in
patients with EVD.
Quality of the evidence
We judged few trials to be at low risk of bias for any of the assessed
domains. Of particular concern is the small number of trials (n
= 3) that used adequate allocation concealment. Where possible
we explored the influence of trials with unclear or high risk of
bias for allocation concealment using sensitivity analyses. Blinding
was not feasible due to the nature of the interventions and this
may have introduced bias, particularly in the assessment of subjec-
tive outcomes. In some trials, attrition between groups might also
have introduced bias. For example, in Banerjee 1994 10 patients
(30%) allocated to the intravenous group were switched to the
intraosseous group because venous access could not be achieved. It
is possible that these patients were more dehydrated, which might
account for the difficulty with venous access. As the trial data were
not presented on an intention-to-treat basis, a favourable effect of
intraosseous access on outcomes may have been diluted.
Also, because the estimated information size for the meta-analysis
(n = 1388) was not achieved for the primary outcome (insertion
failures) for any of the routes compared, we cannot discount the
possibility that the observed increase in risk of insertion failure
associated with the intravenous method compared to both the in-
traosseous and subcutaneous methods are false positives, although
the P values accompanying the pooled effect estimates are very
small (≤ 0.001).
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Potential biases in the review process
As with all systematic reviews, publication and reporting biases
should be considered as potential threats to the validity of the
findings of this review. We undertook comprehensive searching
but cannot discount the possibility that trials, in particular un-
published trials, were not identified.
Also, few trials contributed data to each outcome, which may
suggest some selective outcome reporting. Indeed, comparison of
prespecified outcomes with those given in the final report for the
one trial that was prospectively registered, did suggest selective
outcome reporting. However, this could not be explored for the
other included trials, which had not been prospectively registered.
Wewere also unable to explore the presence of reporting bias using
funnel plots because there were too few trials included in themeta-
analyses.
Two trials reported data for some continuous outcomes asmedians
and ranges (Reades 2011; Slesak 2003). To allow these data to
be included in the meta-analyses, we estimated the corresponding
means and standard deviations using the approach described in
Hozo 2005. However, meta-analysis of the difference in means
is appropriate, assuming that the data are normally distributed.
That these datawere presented asmedians and rangesmay indicate
that their distributions were skewed and not normally distributed.
The estimates of the mean difference based on these data should
therefore be interpreted with caution.
Agreements and disagreements with other
studies or reviews
The findings of this systematic review are largely consistent with
those of other relevant literature reviews. We identified two other
reviews that summarised the results of observational and interven-
tion studies assessing the use of subcutaneous infusion for treat-
ing dehydration in older adults (Remington 2007; Rochon 1997).
The conclusion of both reviews was that subcutaneous infusion is
a safe and feasible alternative to intravenous fluid administration
for treating mild to moderate dehydration in the elderly.
Another article reported the results of a systematic review of ob-
servational and intervention studies assessing the effectiveness of
non-oral and non-intravenous methods for treating dehydration
in children (Rouhani 2011). The authors noted the lack and lim-
ited quality of the evidence, but concluded that the intraosseous
method could be an effective alternative when intravenous access
is not feasible. Although they noted promising results from case
series studies, they also concluded that there was insufficient evi-
dence to recommend the intraperitoneal or subcutaneous method
above other parenteral access methods in this patient group.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There are several different ways of achieving parenteral access in
patients who are unable to meet their fluid requirements enterally.
In view of the large number of cases and the severe resource con-
straints, methods for achieving parenteral access in the context of
Ebola virus disease (EVD) need to be simple, easy and quick, and
must not put healthcare workers at unnecessary risk. The quality
of the evidence in this review is somewhat limited, largely because
of the lack of adequately powered trials at low risk of bias. Al-
though this prevents us from drawing firm conclusions regarding
the magnitude of the difference between parenteral access meth-
ods, useful inferences about the likely direction of effects can be
made for some outcomes.
The choice of method used in clinical practice may depend on site-
specific issues such as the availability and expertise of medical and
nursing staff, patient numbers and local infrastructure. If intra-
venous access can be achieved easily, this facilitates the infusion of
larger volumes of fluid and also allows blood samples to be drawn
for testing (e.g. for EVD or malaria) at the time of insertion. How-
ever, if this is not possible, intraosseous and subcutaneous routes
are alternatives that can be achieved rapidly. The subcutaneous
route may be suitable for patients who are not severely dehydrated
but in whom ongoing fluid losses cannot be met by oral intake.
Given the ease of insertion of subcutaneous lines, they could be
inserted by healthcare workers with minimal medical training.
It is expected that most clinicians are familiar with the intravenous
method, but may be less so with the other methods although these
can be easily taught.
A film to accompany this review can be viewed here.
Implications for research
The quality of the included trials was low. Further comparative
trials of alternative approaches are appropriate if those caring for
patients with EVD remain uncertain about which is the most ef-
fective strategy for securing reliable parenteral access. Importantly,
there is no reliable information on the extent to which the differ-
ent parenteral access devices are dislodged during use. This might
be particularly relevant in the context of the current epidemic of
EVD, where there are shortages of nursing and medical staff, since
the volume of fluid administered might depend on the duration
of parenteral access. Also, there is a lack of data on the impact of
personal protective equipment on parenteral access methods and
whether effects differ in children, which should be addressed by
future trials. There are no data on the relative merits of intraperi-
toneal access. This method has been used to resuscitate severely
dehydrated infants with cholera in whom achieving intravenous
access is difficult (Mahalanabis 1970). Whether it is more effec-
tive than intravenous, intraosseous or subcutaneous access remains
unknown. Future trials should be prospectively registered, have
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secure allocation concealment, adequate sample sizes and should
be reported according to established standards.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Banerjee 1994
Methods Parallel randomised trial
Participants Setting: hospital emergency unit in Chandigarh, India
60 children (aged 3 months to 2 years) with severe dehydration due to diarrhoea and/or
vomiting
• Intravenous group: (n = 30); M/F = NR; mean age (SEM) = 8.6 (1.6) months
• Intraosseous group: (n = 30); M/F = NR; mean age (SEM) = 8.9 (2.0) months
Interventions • Intravenous group: 22 or 24 G Teflon catheter, insertion site not specified
• Intraosseous group: 18 G spinal needle with stylet or 16 to 18 G hypodermic
needle with stylet, insertion site not specified
Both groups were infused with normal saline and/or N/2 saline in 5% dextrose with
potassium 20 mEQ/L, if not contraindicated
Insertions were performed by paediatric residents with 1 year of clinical experience
Outcomes Failure of route placementˆ, defined as failure to secure route within 5 minutes of first
attempt
Time taken to secure access°
Serum sodium°
Serum potassium°
Urea°
Creatinine°
ˆdata analysed as intention-to-treat
°data analysed as-treated
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Participants were “assigned alternately”
Allocation concealment (selection bias) High risk Participants were “assigned alternately”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding introduced
bias, but unclear in which direction the effect estimate would
have been biased
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would have
been biased
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Banerjee 1994 (Continued)
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Low risk We judge that measurement of these outcomes is not likely
to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Data on these outcomes were not reported
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
High risk Access could not be secured in 10 patients in the IV group
who were switched to the IO group. Data on success of in-
sertion were included in the meta-analysis on an intention-
to-treat basis. Time for insertion data were presented and are
therefore included in the meta-analysis according to route
received
Incomplete outcome data (attrition bias)
Clinical outcomes
High risk Data presented and therefore included in the meta-analysis
according to the route received
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Data on these outcomes were not reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
Boullu-Sanchis 2006
Methods Parallel randomised trial
Participants Setting: diabetology department, France
37 patients hospitalised for uncontrolled type 2 diabetes
• Intravenous group: (n = 13); M/F = 8/5; mean age (SD) = 57.9 (2.6)
• Subcutaneous group: (n = 20); M/F = 9/11; mean age (SD) = 59.0 (1.5)
Interventions • Intravenous group: pump continuously administered solution of 0.4 ml regular
insulin in 39.6 ml saline
• Subcutaneous group: continuous infusion with intermittent bolus. Site changed
every 3 days
Unclear who performed the insertions
Outcomes Local site reactionsˆ
ˆdata analysed as intention-to-treat
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Boullu-Sanchis 2006 (Continued)
Random sequence generation (selection
bias)
Unclear risk Described as “randomized by drawing to either group 1 or
group 2”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding introduced
bias, but unclear in which direction the results would have
been biased
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
Unclear risk Data on these outcomes were not reported
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Unclear risk Not applicable (trial does not involve fluid administration)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would have
been biased
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
Unclear risk Data on these outcomes were not reported
Incomplete outcome data (attrition bias)
Clinical outcomes
Unclear risk Data on these outcomes were not reported
Incomplete outcome data (attrition bias)
Subjective outcomes
Low risk 4 patients (2 in each group) were excluded, however we
judged that the reasons for the missing data are unlikely to
be related to outcome
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
Challiner 1994
Methods Parallel randomised trial
Participants Setting: elderly care unit, UK
34 elderly stroke patients requiring parenteral nutrition because of impaired conscious-
ness or dysphagia
• Intravenous group: (n = 17); M/F = 6/11; mean age (range) = 84.2 (71 to 95) years
• Subcutaneous group: (n = 17); M/F = 6/11; mean age (range) = 82.8 (69 to 93)
years
Interventions • Intravenous group: details of route not described
• Subcutaneous group: 10 G butterfly cannula sited on the trunk, axillary, scapular
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Challiner 1994 (Continued)
or thigh area. 1500 units of hyaluronidase added to each bag if infusion ran behind time
Both groups infused with 2 litres of isotonic dextrose-saline per 24 hours over 3 days
Unclear who performed the insertions
Outcomes Local site reactionsˆ
Mortalityˆ
ˆdata analysed as intention-to-treat
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Sequentially numbered, sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding introduced
bias, but unclear in which direction the results would have
been biased
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would have
been biased
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Low risk We judge that measurement of these outcomes is not likely
to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would have
been biased
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
High risk 2 patients allocated to the subcutaneous group were excluded
from the trial analysis - 1 died and 1 developed local oedema
Incomplete outcome data (attrition bias)
Clinical outcomes
Low risk Data for the patient in the subcutaneous group excluded from
the trial analysis have been included in the meta-analysis for
the mortality outcome
Incomplete outcome data (attrition bias)
Subjective outcomes
Low risk Data for the patient in the subcutaneous group excluded from
the trial analysis have been included in the meta-analysis for
the local site reactions (oedema) outcome
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
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Dardaine 1995
Methods Randomised cross-over trial
Participants Setting: hospital, France
6 hospitalised, elderly patients who had been admitted at least 45 days before, for reha-
bilitation after a bone trauma requiring surgery
M/F = 1/5; mean age (SD) = 81.5 (9.8) years
Interventions • Intravenous group: administered into forearm vein
• Subcutaneous group: administered into the anterior wall of the abdomen
Both groups infused with 1000 ml of 5% glucose solution containing 4 g NaCl over 6
hours
Unclear who performed the insertions
Outcomes None of interest to this review
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding intro-
duced bias, but unclear in which direction the results
would have been biased
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would
have been biased
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Unclear risk Data on this outcome were not reported
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Data on this outcome were not reported
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
Low risk No exclusions described
Incomplete outcome data (attrition bias)
Clinical outcomes
Unclear risk Data on this outcome were not reported
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Dardaine 1995 (Continued)
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Data on this outcome were not reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
Delamaire 1992
Methods Parallel randomised trial
Participants Setting: hospital, France
30 elderly patients (average 83 years) requiring rehydration (unable to take sufficient
oral hydration)
• Intravenous group: (n = 15); M/F = 6/11; mean age (SD) = NR
• Subcutaneous group: (n = 15); M/F = NR; mean age (SD) = NR
Interventions • Intravenous group:
• Subcutaneous group:
Both groups infused with 1 litre solution of 2.5% glucose + 4.5g sodium chloride
Unclear who performed the insertions
Outcomes Failures of route replacementˆ, definition of failure not described
Local site reactions (oedema, infection)ˆ
ˆdata analysed as intention-to-treat
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding introduced
bias, but unclear in which direction the results would have
been biased
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would have
been biased
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Unclear risk Data on these outcomes were not reported
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Delamaire 1992 (Continued)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would have
been biased
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
Low risk No exclusions
Incomplete outcome data (attrition bias)
Clinical outcomes
Unclear risk Data on these outcomes were not reported
Incomplete outcome data (attrition bias)
Subjective outcomes
Low risk No exclusions
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
Duems Noriega 2014
Methods Parallel randomised trial
Participants Setting: hospital, Spain
70 patients with mild to moderate dehydration and oral intolerance, aged 65 years and
older, admitted to hospital
• Intravenous group: (n = 33); M/F = 20/14; mean age (SD) = 84.3 (6.6) years
• Subcutaneous group: (n = 34); M/F = 15/18; mean age (SD) = 86.4 (8.5) years
Interventions • Intravenous group: administered through catheters sited at back of the hand,
forearm or inner elbow, avoiding previously damaged areas
• Subcutaneous group: 21 to 25 G needles sited at inside of the thighs, lateral
abdominal wall or the scapular region, avoiding previously damaged areas
Both groups infused up to 1.5 litres per 24 hours of either NaCl 0.9% or glucose 5%
or mixed solution (saline 0.45% + glucose 5%). 20 mEq of potassium chloride could be
added per litre
Unclear who performed the insertions
Outcomes Dislodgementsˆ
Local site reactions (oedema, infection)ˆ
Mortalityˆ
Patient discomfort (agitation)ˆ
Volume of fluid infusedˆ
Creatinineˆ
Ureaˆ
ˆdata analysed as intention-to-treat
Notes Trial report in Spanish
Risk of bias
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Duems Noriega 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Randomisation by mixed blocks of 6 sealed envelopes. Each
block with 3 cards with the treatment IV and 3 with SC
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding introduced
bias, but unclear in which direction the results would have
been biased
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would have
been biased
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Low risk We judge that measurement of these outcomes is not likely
to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would have
been biased
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
High risk 3 patients who died during the study period were excluded
from the trial analysis
Incomplete outcome data (attrition bias)
Clinical outcomes
High risk Data for the 3 patients (2 in the intravenous group, 1 in the
subcutaneous group) who died during the study period were
excluded from the trial analysis. These data have been in-
cluded in themeta-analysis for the mortality outcome. How-
ever, risk of bias remains for renal function outcomes
Incomplete outcome data (attrition bias)
Subjective outcomes
High risk 3 patients who died during the study period were excluded
from the trial analysis
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
Harbo 2009
Methods Randomised cross-over trial
Participants Setting: Aarhus University Hospital, Denmark
10 intravenous immunoglobulin responsive patients with multifocal motor neuropathy
M/F = 4/5; mean age (SD) = 49.2 (10.51) years
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Harbo 2009 (Continued)
Interventions • Intravenous group: administered during hospital admission through a permanent
IV catheter inserted into the subclavian vein (n = 2) or peripheral vein (n = 7)
• Subcutaneous group: syringe pump and butterfly needle into tissue at the
abdominal wall. Received 80 to 155 ml at 4 to 8 injection sites each week at an
infusion time of 2 to 4 hours
Both groups infused with immunoglobulin
Unclear who performed the IV insertions; SC insertions performed initially by nurse
and then were self administered
Outcomes Local site reactions (erythema, oedema, infection)ˆ
Painˆ (how this was assessed is not described in the report)
ˆdata analysed as intention-to-treat
data included in review as a parallel trial; this approach leads to a unit of analysis error,
causing the CIs to be too wide and the trial to receive too little weight
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Pharmacy-controlled
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding intro-
duced bias, but unclear in which direction the results
would have been biased
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
Unclear risk Data on these outcomes were not reported
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Unclear risk Not applicable (trial does not involve fluid administra-
tion)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would
have been biased
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
Unclear risk Data on these outcomes were not reported
Incomplete outcome data (attrition bias)
Clinical outcomes
Unclear risk Data on these outcomes were not reported
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Harbo 2009 (Continued)
Incomplete outcome data (attrition bias)
Subjective outcomes
Low risk No post-randomisation exclusions
Selective reporting (reporting bias) Unclear risk Registered after start of recruitment (NCT00268788).
Adverse events listed as a secondary outcomes
Harvey 1987
Methods Randomised cross-over trial
Participants Setting: London, UK
9 patients with malignant disease
M/F = NR; mean age (SD) = NR
Interventions • Intravenous group: into forearm vein via Teflon catheter
• Subcutaneous group: into anterior abdominal wall via 25 G steel needle
15 mg bleomycin in saline with 100 mg hydrocortisone
Unclear who performed the insertions
Outcomes Local site reactions, although insufficient data presented for meta-analysis
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding intro-
duced bias, but unclear in which direction the results
would have been biased
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
Unclear risk Data on these outcomes were not reported
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Unclear risk Not applicable (trial does not involve fluid administra-
tion)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would
have been biased
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Harvey 1987 (Continued)
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
Unclear risk Data on these outcomes were not reported
Incomplete outcome data (attrition bias)
Clinical outcomes
Unclear risk Data on these outcomes were not reported
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk No exclusions reported, although presented data were in-
sufficient for meta-analysis
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
Hubble 2001
Methods Randomised cross-over trial
Participants Setting: hospital training laboratory, USA
13 students of the senior class of baccalaureate degree paramedical programme, recently
trained in both methods
M/F = NR; mean age (SD) = NR
Interventions • Saphenous vein cutdown: at the ankle in a cadaver using standard technique with
insertion of an IV cannula under direct visualisation
• Intraosseous group: using the BIG® into the proximal tibia of a cadaver
Both access routes connected to a 1000 ml bag of NaCl solution
Insertions performed by members of senior class of a baccalaureate degree paramedical
programme
Outcomes Failure of route placementˆ (defined as inability to initiate fluid flow)
Time to infusionˆ
ˆdata analysed as intention-to-treat
data included in review as a parallel trial; this approach leads to a unit of analysis error,
causing the CIs to be too wide and the trial to receive too little weight
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding intro-
duced bias, but unclear in which direction the results
would have been biased
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Hubble 2001 (Continued)
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would
have been biased
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Unclear risk Not applicable (simulated using a cadaver)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Data on these outcomes were not reported
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
Low risk No exclusions
Incomplete outcome data (attrition bias)
Clinical outcomes
Unclear risk Not applicable (simulated using a cadaver)
Incomplete outcome data (attrition bias)
Subjective outcomes
Low risk No exclusions
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
Hägglund 1998
Methods Parallel randomised trial
Participants Setting: Huddinge Hospital, Sweden
38 adult patients receiving bone marrow transplants from related donor
• Intravenous group: (n = 20); M/F = NR; median age (range) = 38 (19 to 54) years
• Intraosseous group: (n = 9); M/F = NR; median age (range) = 38 (20 to 50) years
Interventions • Intravenous group: details of route not described
• Intraosseous group: 2 bone marrow aspiration needles inserted into each side of
the posterior iliac crests under local anaesthesia. Infusion given with or without
overpressure using a 50 cc syringe
Both groups infused with bone marrow
Unclear who performed the insertions
Outcomes Local site reactions (infection)
data not analysed on an intention-to-treat basis; data on patient who switched treatment
excluded from trial analysis
Notes -
Risk of bias
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Hägglund 1998 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding introduced
bias, but unclear in which direction the results would have
been biased
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
Unclear risk Data on these outcomes were not reported
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Unclear risk Not applicable (trial does not involve fluid administration)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would have
been biased
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
Unclear risk Data on these outcomes were not reported
Incomplete outcome data (attrition bias)
Clinical outcomes
Unclear risk Not applicable (trial does not involve fluid administration)
Incomplete outcome data (attrition bias)
Subjective outcomes
High risk Apparent from the report that 1 patient in the IO group
switched to receive half the volume as an IV infusion because
of severe pain and was excluded from the analysis
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
Lamhaut 2010 (no PPE)
Methods Randomised cross-over trial
Participants Setting: pre-hospital department of a hospital, France
25 pre-hospital emergency professionals (9 nurses and 16 physicians)
M/F = NR; mean age (SD) = NR
Interventions • Intravenous group: single-use 18 G peripheral intravenous catheter inserted into a
training manikin
• Intravenous group + CBRN: as above while wearing CBRN protective equipment
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Lamhaut 2010 (no PPE) (Continued)
• Intraosseous group: using EZ-IO® 15 G needle inserted into training manikin
• Intraosseous group + CBRN: as above while wearing CBRN protective equipment
Both access routes connected to bag of fluid solution
Insertions performed by pre-hospital emergency professionals (9 nurses and 16 physi-
cians)
Outcomes Insertion failuresˆ, not clearly defined, described only as “failure of an IV or IO access
attempt, including the case of absence of fluid after connection of the infusion line to
the vascular access”
Time to infusionˆ
ˆdata analysed as intention-to-treat
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding intro-
duced bias, but unclear in which direction the results
would have been biased
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would
have been biased
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Unclear risk Not applicable (simulated using manikin)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Data on these outcomes were not reported
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
Low risk No exclusions
Incomplete outcome data (attrition bias)
Clinical outcomes
Unclear risk Not applicable (simulated using a manikin)
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Data on these outcomes were not reported
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Lamhaut 2010 (no PPE) (Continued)
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
Lamhaut 2010 (with PPE)
Methods Randomised cross-over trial
Participants Setting: pre-hospital department of a hospital, France
25 pre-hospital emergency professionals (9 nurses and 16 physicians)
M/F = NR; mean age (SD) = NR
Interventions • Intravenous group + CBRN: as above while wearing CBRN protective equipment
• Intraosseous group + CBRN: as above while wearing CBRN protective equipment
Both access routes connected to bag of fluid solution
Outcomes Insertion failuresˆ, not clearly defined, described only as “failure of an IV or IO access
attempt, including the case of absence of fluid after connection of the infusion line to
the vascular access”
Time to infusionˆ
ˆdata analysed as intention-to-treat
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding intro-
duced bias, but unclear in which direction the results
would have been biased
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would
have been biased
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Unclear risk Not applicable (trial does not involve fluid administra-
tion)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Data on these outcomes were not reported
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Lamhaut 2010 (with PPE) (Continued)
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
Low risk No exclusions
Incomplete outcome data (attrition bias)
Clinical outcomes
Unclear risk Not applicable (trial does not involve fluid administra-
tion)
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Data on these outcomes were not reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
Liebl 2009
Methods Randomised cross-over trial
Participants Setting: centres in Netherlands, France, Austria, Germany and Switzerland
61* patients with type 1 diabetes with frequent hypoglycaemia and/or HbA1c > 7.0%
M/F = 44/16; mean age (SD) = 50.5 (10.8) years
(*1 patient excluded)
Interventions • Intraperitoneal: using the DiaPort system, implanted under general anaesthesia
into the subcutaneous tissue of the abdominal wall. Insulin is infused into the
abdominal cavity
• Subcutaneous group: continuous infusion of insulin lispro
Unclear who performed the insertions
Outcomes Local site reactions (infections and inflammations)°
Pain° (how this was assessed is not described in the report)
°data analysed as-treated
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding intro-
duced bias, but unclear in which direction the results
would have been biased
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Liebl 2009 (Continued)
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
Unclear risk Data on these outcomes were not reported
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Unclear risk Not applicable (trial does not involve fluid administra-
tion)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would
have been biased
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
Unclear risk Data on these outcomes were not reported
Incomplete outcome data (attrition bias)
Clinical outcomes
Unclear risk Not applicable (trial does not involve fluid administra-
tion)
Incomplete outcome data (attrition bias)
Subjective outcomes
High risk Large number of dropouts during study - 15 IP patients
and 9 SC patients dropped out during first treatment
period followed by 9 IP patients and 3 SC patients during
the second treatment period
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
O’Keeffe 1996
Methods Parallel randomised trial
Participants Setting: acute geriatric unit, UK
60 elderly patients with cognitive impairment judged to require parenteral fluids for at
least 48 hours because of mild dehydration or poor oral intake
• Intravenous group: (n = 30); M/F = 13/17; mean age (SD) = 84 (7) years
• Subcutaneous group: (n = 30); M/F = 10/20; mean age (SD) = 81 (6) years
Interventions • Intravenous group: administered through an 18 or 20 G cannula in forearm vein
• Subcutaneous group: administered in the infraclavicular, scapular, abdominal or
thigh areas through a 21 G butterfly cannula
Up to 2 litres of any combination of 0.9% normal saline, 0.45% normal saline and 5%
dextrose
Unclear who performed the insertions
Outcomes Local site reactions (oedema)
Patient discomfort (agitation related to cannula or drip)
Volume of fluids infused
data not analysed on an intention-to-treat basis; data on patient who switched treatment
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O’Keeffe 1996 (Continued)
excluded from trial analysis
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table
Allocation concealment (selection bias) Unclear risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding introduced
bias, but unclear in which direction the results would have
been biased
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
Unclear risk Data on these outcomes were not reported
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Unclear risk Data on these outcomes were not reported
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would have
been biased
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
Unclear risk Data on these outcomes were not reported
Incomplete outcome data (attrition bias)
Clinical outcomes
High risk 2 patients were excluded from the trial analyses (1 IV patient
was switched to SC fluids and 1 patient in the SC group died)
. However, the mortality data were included in the meta-
analysis
Incomplete outcome data (attrition bias)
Subjective outcomes
High risk 2 patients were excluded from the trial analyses (1 IV patient
was switched to SC fluids and 1 patient in the SC group died)
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
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Reades 2011
Methods Parallel randomised trial
Participants Setting: pre-hospital setting in North Carolina, USA
182 adult patients with non-traumatic out-of-hospital cardiac arrest
• Intravenous group: (n = 67); M/F = 42/25; mean age (SD) = 64.7 (2.2) years
• Intraosseous group 1: (n = 51); M/F = 36/15; mean age (SD) = 61.2 (2.4) years
• Intraosseous group 2: (n = 64); M/F = 41/23; mean age (SD) = 66.9 (2.1) years
Interventions • Intravenous group: inserted into any accessible peripheral vein but preferably at
the antecubital fossa
• Intraosseous group 1: inserted into proximal humerus defined as the greater
tubercle of the anterior humeral head 1 cm proximal to the surgical neck of humerus
using EZ-IO®
• Intraosseous group 2: inserted into the proximal tibia located medial to the tibial
tuberosity, or just below the patella along the flat aspect of the tibia using EZ-IO®
Data for intraosseous groups 1 and 2 were combined for the purpose of meta-analysis
Insertions performed by paramedics
Outcomes Failure of route placementˆ (’first-attempt’ success was defined for IO insertion as secure
placement of the catheter within the bone cavity and for IV insertion as secure placement
within a peripheral vein. If initial access was not successful, the paramedics used their
own judgement for choosing the subsequent site)
Time taken to secure access‡ˆ
Average number of insertion attempts*‡ˆ
Dislodgements of access method*ˆ
Paramedics’ reported comfort with insertion method*ˆ
Volume of fluid infused‡ˆ
*not specified in trial registration record
‡mean and SD estimated from reported median and IQR for analysis - moderate sample size
therefore SD calculated as = range/4
ˆdata analysed as intention-to-treat
Notes Prior to the study, all paramedics were trained on IO insertions using EZ-IO® on a
human cadaver
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) High risk 300 note cards were prepared in advance and labelled with
a vascular access method. Each note card was sealed in a
blank, numbered envelope. Each crew randomly selected and
opened an envelope prior to every shift. The route selected
was applied to the crew’s first cardiac arrest of the day
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Reades 2011 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding introduced
bias, but unclear in which direction the results would have
been biased
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would have
been biased
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Unclear risk Data on these outcomes were not reported
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would have
been biased
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
Low risk The allocatedmethodwas not used in 13 patients due to “hu-
man error or situations beyond the control of the paramedic”
(9 in the humeral IO group and 4 in the IV group). Success
of insertion data was analysed on both an intention-to-treat
and as-treated basis. Other outcomes were analysed as inten-
tion-to-treat
Incomplete outcome data (attrition bias)
Clinical outcomes
Low risk Analysed as intention-to-treat
Incomplete outcome data (attrition bias)
Subjective outcomes
Low risk Analysed as intention-to-treat
Selective reporting (reporting bias) High risk Prospectively registered (NCT01119807). Additional sec-
ondary outcomes were reported in the final report that were
not mentioned in the registration record
Selam 1983
Methods Randomised cross-over trial
Participants Setting: hospital, France
6 patients with insulin-dependent diabetes
M/F = 2/7; mean age (SE) = 35 (4) years
Interventions • Intravenous group: implanted either surgically in the cephalic vein or directly in
the subclavian vein by using a needle puncture technique
• Subcutaneous group: catheter implanted in the subcutaneous tissue of the lateral
abdomen
• Intraperitoneal group: inserted surgically into the lateral abdomen under local
anaesthesia through a 5 cm subumbilical laparotomy
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Selam 1983 (Continued)
All groups were infused insulin
Unclear who performed the insertions
Outcomes Local site reactionsˆ
Painˆ (how this was assessed is not described in the report)
ˆdata analysed as intention-to-treat
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding intro-
duced bias, but unclear in which direction the results
would have been biased
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
Unclear risk Data on these outcomes were not reported
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Unclear risk Not applicable (trial does not involve fluid administra-
tion)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the effect estimate
may have been biased
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
Unclear risk Data on these outcomes were not reported
Incomplete outcome data (attrition bias)
Clinical outcomes
Unclear risk Data on these outcomes were not reported
Incomplete outcome data (attrition bias)
Subjective outcomes
Low risk No exclusions
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
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Slesak 2003
Methods Parallel randomised trial
Participants Setting: hospital geriatric department, Germany
96 hospitalised patients aged 60 years and over with mild to moderate dehydration
• Intravenous group: (n = 48); M/F = 12/36; mean age (SD) = 85.3 (5.8) years
• Subcutaneous group: (n = 14); M/F = 17/31; mean age (SD) = 85.3 (7.6) years
Interventions • Intravenous group: 18 to 22 G peripheral catheters
• Subcutaneous group: 21 G butterfly into thigh, abdomen or thorax
Both groups infused with half-normal saline-glucose solutions for as long as clinically
necessary
Insertions performed by nurses and doctors
Outcomes Time to infusion¤ˆ
Time with functional access¤ˆ
Local site reactions (oedema, erythema, cellulitis, phlebitis, pain)ˆ
Doctors and nurses feasibility of route scores‡ˆ (’feasibility’ described in the trial report
as “with regard to the practical implementation and the occurrence of complications”)
Patient discomfort‡ˆ (measured using a Likert-like scale, points ranging from 1 = very
good to 6 = very bad)
Volume of fluid infused¤ˆ
Serum sodiumˆ
Creatinine‡ˆ
‡mean and SD estimated from reported median and IQR for analysis - moderate sample size
therefore SD calculated as = range/4
¤mean and SD estimated from reported median andminimum-maximum values for analysis
- moderate sample size therefore SD calculated as = range/4
ˆdata analysed as intention-to-treat
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Shuffled blocks of 6 sealed envelopes, each containing 3 of
each treatment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding introduced
bias, but unclear in which direction the results would have
been biased
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would have
been biased
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Slesak 2003 (Continued)
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Low risk We judge that measurement of these outcomes is not likely
to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would have
been biased
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
Low risk No exclusions reported. However, 13 patients in the SC
group were switched to IV and 17 patients in the IV group
were switched to SC. Data were analysed according to inten-
tion-to-treat
Incomplete outcome data (attrition bias)
Clinical outcomes
Low risk No exclusions reported. However, 13 patients in the SC
group were switched to IV and 17 patients in the IV group
were switched to SC. Data were analysed according to inten-
tion-to-treat
Incomplete outcome data (attrition bias)
Subjective outcomes
Low risk No exclusions reported. However, 13 patients in the SC
group were switched to IV and 17 patients in the IV group
were switched to SC. Data were analysed according to inten-
tion-to-treat
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
Spandorfer 2005
Methods Parallel randomised trial
Participants Setting: 24 hospitals, USA
148 children with mild to moderate dehydration aged 1 month to < 10 years
• Intravenous group: (n = 75); M/F = 39/36; mean age (range) = 2.4 (2.07) years
• Subcutaneous group: (n = 73); M/F = 34/39; mean age (range) = 2.1 (1.72) years
Interventions • Intravenous group: details of route not described
• Subcutaneous group: details of route not described. Hyaluronidase used in all
patients
20 ml/kg isotonic fluids over 1 hour
Insertions performed by “health care providers”
Outcomes Failure of route placementˆ (definition of failure not specified in the report)
Time to infusionˆ
Local site reactions (erythema, oedema, swelling)ˆ
Clinicians’ perception of ease of route to performˆ
Patient discomfortˆ (assessed using the FLACC scale for those < 3 years or FACES Pain
Rating scale for those ≥ 3 years)
Volume of fluid infusedˆ
ˆdata analysed as intention-to-treat
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Spandorfer 2005 (Continued)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible. Likely that lack of blinding introduced
bias, but unclear in which direction the results would have
been biased
Blinding of outcome assessment (detection
bias)
Outcomes related to parenteral route inser-
tion
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would have
been biased
Blinding of outcome assessment (detection
bias)
Clinical outcomes
Unclear risk Data on these outcomes were not reported
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Likely that lack of blinding biased the assessment of these
outcomes; unclear in which direction the results would have
been biased
Incomplete outcome data (attrition bias)
Outcomes related to parenteral route inser-
tion
Low risk 1 patient in the IV group was excluded from the trial at
the request of the parent. 15 patients in the IV group were
switched to SC. Both intention-to-treat and as-treated data
are presented
Incomplete outcome data (attrition bias)
Clinical outcomes
Unclear risk Data on these outcomes were not reported
Incomplete outcome data (attrition bias)
Subjective outcomes
Low risk 1 patient in the IV group was excluded from the trial at
the request of the parent. 15 patients in the IV group were
switched to SC. Both intention-to-treat and as-treated data
are presented
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
CBRN: chemical, biological, radiological and nuclear (protective equipment)
CI: confidence interval
F: female
FLACC scale: Face, Legs, Activity, Cry, Consolability scale
IO: intraosseous
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IP: intraperitoneal
IQR: interquartile range
IV: intravenous
M: male
NaCl: sodium chloride
NR: not reported
SC: subcutaneous
SD: standard deviation
SE: standard error
SEM: standard error of the mean
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Chavez-Negrete 1991 Trial in which patients were randomised to receive an infusion of 7.5% NaCl + 6% dextran 60 or Ringer’s
lactate. Within each arm some of the patients received the assigned fluids intravenously and others in-
traosseously. However, the parenteral method for infusion was not determined at random, so the trial was
not eligible for inclusion in this review
Ismael 2012 The parenteral methods under study were not used for infusion of fluids or medication
Klemenz 1997 Not a RCT; the article is a letter describing the subcutaneous and intravenous methods for delivering fluids
Koshy 2005 Not relevant to the review question; the purpose of the trial was to assess the effects of the infusion of
analgesia on cancer pain
Lee 2009 The parenteral methods under study were not used for infusion of fluids or medication
Mace 2013 Not a RCT. The study evaluated the cost-effectiveness of subcutaneous fluid adminsitration compared to
intravenous fluid administration in children with mild to moderate dehydration
Mahalanabis 1970 Not aRCT.The study explores the effect of intraperitoneal routes in dehydrated patients. All patients received
fluids via both the intravenous and intraperitoneal routes
Moulin 1991 Not relevant to the review question; the purpose of the trial was to assess the effects of the infusion of
analgesia on cancer pain
Nelson 1997 Cross-over study comparing intravenous and subcutaneous morphine. However, the order in which the
patients received the methods was not randomised - all received intravenous morphine followed by subcu-
taneous morphine
Paxton 2009 Not a RCT. This is a prospective cohort study exploring intraosseous and intravenous access
Rajani 2011 Comparison of umbilical venous access versus intraosseous access under simulated conditions. Umbilical
venous access was not an eligible type of intervention
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(Continued)
Ransome-Kuti 1969 Not aRCT.This is a case series report describing the outcomes of 91 dehydrated babieswhowere administered
fluids via the intraperitoneal route
Robinson 1993 The parenteral methods under study were not used for infusion of fluids or medication
Soremekun 2009 Cross-over study comparing intravenous and subcutaneous glucose. However, the order in which the patients
received the methods was not randomised - all received intravenous access first followed by subcutaneous
access
Tighe 1993 Not a RCT. This is a case series report describing the outcomes of 9 dehydrated children who were adminis-
tered fluids via the intravenous, intraosseous or intraperitoneal route. The route received was not allocated
at random
NaCl: sodium chloride
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Intravenous versus intraosseous access
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Insertion failures 2 242 Risk Ratio (M-H, Fixed, 95% CI) 3.89 [2.39, 6.33]
2 Insertion failures (subgroup
analysis child vs adult)
2 242 Risk Ratio (M-H, Fixed, 95% CI) 3.89 [2.39, 6.33]
2.1 Adult 1 182 Risk Ratio (M-H, Fixed, 95% CI) 3.24 [2.00, 5.27]
2.2 Child 1 60 Risk Ratio (M-H, Fixed, 95% CI) 21.0 [1.29, 342.93]
3 Time to infusion/placement 4 Mean Difference (Fixed, 95% CI) Totals not selected
4 Average number of insertion
attempts
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Dislodgement of device during
infusion
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Local site reactions 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Infection 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Clinician’s perception
of ease/feasibility of
administration
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Volume of fluids transfused 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9 Electrolyte level 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Sodium 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Potassium 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Renal function 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 Urea 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 Creatinine 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Intravenous versus subcutaneous access
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Insertion failures 3 238 Risk Ratio (M-H, Fixed, 95% CI) 14.79 [2.87, 76.08]
2 Insertion failures (sensitivity
analysis - trial(s) with adequate
allocation concealment)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Insertion failures (subgroup
analysis child vs adult)
3 238 Risk Ratio (M-H, Fixed, 95% CI) 14.79 [2.87, 76.08]
3.1 Adult 2 90 Risk Ratio (M-H, Fixed, 95% CI) 6.0 [0.76, 47.39]
3.2 Child 1 148 Risk Ratio (M-H, Fixed, 95% CI) 32.13 [1.96, 525.87]
4 Time to infusion/placement 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Dislodgement of device during
infusion
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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6 Time with functional access
(days)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7 Local site reactions 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Any 5 247 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.80, 1.02]
7.2 Erythema 4 296 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.31, 0.61]
7.3 Swelling 1 148 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.17, 0.41]
7.4 Infection 4 211 Risk Ratio (M-H, Fixed, 95% CI) 3.70 [1.06, 12.88]
7.5 Phlebitis 3 181 Risk Ratio (M-H, Fixed, 95% CI) 5.04 [1.14, 22.30]
7.6 Oedema 7 453 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.25, 0.72]
8 Local site reactions (sensitivity
analysis - trial(s) with adequate
allocation concealment)
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Any 3 202 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.79, 0.96]
8.2 Erythema 3 200 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.22, 0.49]
8.3 Swelling 1 148 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.17, 0.41]
8.4 Infection 1 18 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.14, 65.16]
8.5 Phlebitis 1 18 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.14, 65.16]
8.6 Oedema 3 202 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.06, 1.15]
9 Clinicians’ scores of feasibility of
insertion
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Doctors’ scores 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Nurses’ scores 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Clinician’s perception of
difficulty of insertion
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
11 Patients’ discomfort 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 Pain 3 262 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.83, 1.22]
11.2 Agitation 2 125 Risk Ratio (M-H, Fixed, 95% CI) 1.84 [1.26, 2.70]
12 Patients’ discomfort (sensitivity
analysis - trial(s) with adequate
allocation concealment)
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Pain 2 166 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.81, 1.16]
13 Patient discomfort score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14 Mortality 2 106 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.18, 5.92]
15 Mortality (sensitivity analysis -
trial(s) with adequate allocation
concealment)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
16 Volume of fluids transfused 4 Mean Difference (IV, Fixed, 95% CI) Totals not selected
17 Volume of fluids transfused
(sensitivity analysis - trial(s)
with adequate allocation)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
18 Electrolyte level 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
18.1 Sodium 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Markers of renal function 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
19.1 Urea 1 67 Mean Difference (IV, Fixed, 95% CI) -11.29 [-24.69, 2.
11]
19.2 Creatinine 2 138 Mean Difference (IV, Fixed, 95% CI) -0.08 [-0.33, 0.16]
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Comparison 3. Saphenous vein cutdown versus intraosseous access
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Insertion failures 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Time to infusion/placement
(seconds)
1 Mean Difference (Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Intravenous versus intraosseous access, Outcome 1 Insertion failures.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 1 Intravenous versus intraosseous access
Outcome: 1 Insertion failures
Study or subgroup Intravenous Intraosseous Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Banerjee 1994 10/30 0/30 3.6 % 21.00 [ 1.29, 342.93 ]
Reades 2011 34/67 18/115 96.4 % 3.24 [ 2.00, 5.27 ]
Total (95% CI) 97 145 100.0 % 3.89 [ 2.39, 6.33 ]
Total events: 44 (Intravenous), 18 (Intraosseous)
Heterogeneity: Chi2 = 1.94, df = 1 (P = 0.16); I2 =48%
Test for overall effect: Z = 5.45 (P < 0.00001)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours intravenous Favours intraosseous
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Analysis 1.2. Comparison 1 Intravenous versus intraosseous access, Outcome 2 Insertion failures (subgroup
analysis child vs adult).
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 1 Intravenous versus intraosseous access
Outcome: 2 Insertion failures (subgroup analysis child vs adult)
Study or subgroup Intravenous Intraosseous Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adult
Reades 2011 34/67 18/115 96.4 % 3.24 [ 2.00, 5.27 ]
Subtotal (95% CI) 67 115 96.4 % 3.24 [ 2.00, 5.27 ]
Total events: 34 (Intravenous), 18 (Intraosseous)
Heterogeneity: not applicable
Test for overall effect: Z = 4.75 (P < 0.00001)
2 Child
Banerjee 1994 10/30 0/30 3.6 % 21.00 [ 1.29, 342.93 ]
Subtotal (95% CI) 30 30 3.6 % 21.00 [ 1.29, 342.93 ]
Total events: 10 (Intravenous), 0 (Intraosseous)
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.033)
Total (95% CI) 97 145 100.0 % 3.89 [ 2.39, 6.33 ]
Total events: 44 (Intravenous), 18 (Intraosseous)
Heterogeneity: Chi2 = 1.94, df = 1 (P = 0.16); I2 =48%
Test for overall effect: Z = 5.45 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.67, df = 1 (P = 0.20), I2 =40%
0.002 0.1 1 10 500
Favours intravenous Favours intraosseous
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Analysis 1.3. Comparison 1 Intravenous versus intraosseous access, Outcome 3 Time to infusion/placement.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 1 Intravenous versus intraosseous access
Outcome: 3 Time to infusion/placement
Study or subgroup Intravenous Intraosseous Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Banerjee 1994 20 40 62 (14.76) 62.00 [ 33.07, 90.93 ]
Lamhaut 2010 (no PPE) 25 25 20 (4.8) 20.00 [ 10.59, 29.41 ]
Lamhaut 2010 (with PPE) 25 25 39 (4) 39.00 [ 31.16, 46.84 ]
Reades 2011 67 115 8.14 (11.64) 8.14 [ -14.67, 30.95 ]
-100 -50 0 50 100
Favours intravenous Favours intraosseous
Analysis 1.4. Comparison 1 Intravenous versus intraosseous access, Outcome 4 Average number of
insertion attempts.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 1 Intravenous versus intraosseous access
Outcome: 4 Average number of insertion attempts
Study or subgroup Intravenous Intraosseous
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Reades 2011 67 1 (0.25) 115 1 (0.17) 0.0 [ -0.07, 0.07 ]
-0.5 -0.25 0 0.25 0.5
Favours intravenous Favours intraosseous
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Analysis 1.5. Comparison 1 Intravenous versus intraosseous access, Outcome 5 Dislodgement of device
during infusion.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 1 Intravenous versus intraosseous access
Outcome: 5 Dislodgement of device during infusion
Study or subgroup Intravenous Intraosseous Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Reades 2011 4/67 13/115 0.53 [ 0.18, 1.55 ]
0.01 0.1 1 10 100
Favours intravenous Favours intraosseous
Analysis 1.6. Comparison 1 Intravenous versus intraosseous access, Outcome 6 Local site reactions.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 1 Intravenous versus intraosseous access
Outcome: 6 Local site reactions
Study or subgroup Intravenous Intraosseous Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Infection
Ha¨gglund 1998 6/20 0/8 5.57 [ 0.35, 88.77 ]
0.01 0.1 1 10 100
Favours intravenous Favours intraosseous
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Analysis 1.7. Comparison 1 Intravenous versus intraosseous access, Outcome 7 Clinician’s perception of
ease/feasibility of administration.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 1 Intravenous versus intraosseous access
Outcome: 7 Clinician’s perception of ease/feasibility of administration
Study or subgroup Intravenous Intraosseous Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Reades 2011 2/67 23/115 0.15 [ 0.04, 0.61 ]
0.01 0.1 1 10 100
Favours intravenous Favours intraosseous
Analysis 1.8. Comparison 1 Intravenous versus intraosseous access, Outcome 8 Volume of fluids transfused.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 1 Intravenous versus intraosseous access
Outcome: 8 Volume of fluids transfused
Study or subgroup Intravenous Intraosseous
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Reades 2011 67 800 (125) 115 400 (93.06) 400.00 [ 365.57, 434.43 ]
-500 -250 0 250 500
Favours intraosseous Favours intravenous
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Analysis 1.9. Comparison 1 Intravenous versus intraosseous access, Outcome 9 Electrolyte level.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 1 Intravenous versus intraosseous access
Outcome: 9 Electrolyte level
Study or subgroup Intravenous Intraosseous
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sodium
Banerjee 1994 20 132 (8.9) 40 133 (6.3) -1.00 [ -5.36, 3.36 ]
2 Potassium
Banerjee 1994 20 3.9 (5.8) 40 4.3 (1.3) -0.40 [ -2.97, 2.17 ]
-4 -2 0 2 4
Higher in intraosseous Higher in intravenous
Analysis 1.10. Comparison 1 Intravenous versus intraosseous access, Outcome 10 Renal function.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 1 Intravenous versus intraosseous access
Outcome: 10 Renal function
Study or subgroup Intravenous Intraosseous
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Urea
Banerjee 1994 20 14 (8.9) 40 19 (12.65) -5.00 [ -10.53, 0.53 ]
2 Creatinine
Banerjee 1994 20 115 (18) 40 150 (18) -35.00 [ -44.66, -25.34 ]
-50 -25 0 25 50
Favours intravenous Favours intraosseous
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Analysis 2.1. Comparison 2 Intravenous versus subcutaneous access, Outcome 1 Insertion failures.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 1 Insertion failures
Study or subgroup Intravenous Subcutaneous Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Delamaire 1992 4/15 0/15 33.2 % 9.00 [ 0.53, 153.79 ]
O’Keeffe 1996 1/30 0/30 33.2 % 3.00 [ 0.13, 70.83 ]
Spandorfer 2005 16/75 0/73 33.6 % 32.13 [ 1.96, 525.87 ]
Total (95% CI) 120 118 100.0 % 14.79 [ 2.87, 76.08 ]
Total events: 21 (Intravenous), 0 (Subcutaneous)
Heterogeneity: Chi2 = 1.39, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 3.22 (P = 0.0013)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours intravenous Favours subcutaneous
Analysis 2.2. Comparison 2 Intravenous versus subcutaneous access, Outcome 2 Insertion failures
(sensitivity analysis - trial(s) with adequate allocation concealment).
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 2 Insertion failures (sensitivity analysis - trial(s) with adequate allocation concealment)
Study or subgroup Intravenous Subcutaneous Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Spandorfer 2005 16/75 0/73 32.13 [ 1.96, 525.87 ]
0.002 0.1 1 10 500
Favours intravenous Favours subcutaneous
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Analysis 2.3. Comparison 2 Intravenous versus subcutaneous access, Outcome 3 Insertion failures
(subgroup analysis child vs adult).
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 3 Insertion failures (subgroup analysis child vs adult)
Study or subgroup Intravenous Subcutaneous Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adult
Delamaire 1992 4/15 0/15 33.2 % 9.00 [ 0.53, 153.79 ]
O’Keeffe 1996 1/30 0/30 33.2 % 3.00 [ 0.13, 70.83 ]
Subtotal (95% CI) 45 45 66.4 % 6.00 [ 0.76, 47.39 ]
Total events: 5 (Intravenous), 0 (Subcutaneous)
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
2 Child
Spandorfer 2005 16/75 0/73 33.6 % 32.13 [ 1.96, 525.87 ]
Subtotal (95% CI) 75 73 33.6 % 32.13 [ 1.96, 525.87 ]
Total events: 16 (Intravenous), 0 (Subcutaneous)
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
Total (95% CI) 120 118 100.0 % 14.79 [ 2.87, 76.08 ]
Total events: 21 (Intravenous), 0 (Subcutaneous)
Heterogeneity: Chi2 = 1.39, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 3.22 (P = 0.0013)
Test for subgroup differences: Chi2 = 0.90, df = 1 (P = 0.34), I2 =0.0%
0.002 0.1 1 10 500
Favours intravenous Favours subcutaneous
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Analysis 2.4. Comparison 2 Intravenous versus subcutaneous access, Outcome 4 Time to
infusion/placement.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 4 Time to infusion/placement
Study or subgroup Intravenous Subcutaneous
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Slesak 2003 48 300 (420) 48 180 (135) 120.00 [ -4.80, 244.80 ]
-200 -100 0 100 200
Favours intravenous Favours subcutaneous
Analysis 2.5. Comparison 2 Intravenous versus subcutaneous access, Outcome 5 Dislodgement of device
during infusion.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 5 Dislodgement of device during infusion
Study or subgroup Intravenous Subcutaneous Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Duems Noriega 2014 11/33 3/34 3.78 [ 1.16, 12.34 ]
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Analysis 2.6. Comparison 2 Intravenous versus subcutaneous access, Outcome 6 Time with functional
access (days).
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 6 Time with functional access (days)
Study or subgroup Intravenous Subcutaneous
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Slesak 2003 48 2.8 (2.13) 48 2 (2.13) 0.80 [ -0.05, 1.65 ]
-4 -2 0 2 4
Favours intravenous Favours subcutaneous
Analysis 2.7. Comparison 2 Intravenous versus subcutaneous access, Outcome 7 Local site reactions.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 7 Local site reactions
Study or subgroup Intravenous Subcutaneous Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any
Boullu-Sanchis 2006 6/13 0/20 0.4 % 19.50 [ 1.19, 319.33 ]
Challiner 1994 1/17 2/19 2.1 % 0.56 [ 0.06, 5.63 ]
Harbo 2009 3/9 6/9 6.7 % 0.50 [ 0.18, 1.40 ]
Selam 1983 1/6 6/6 7.3 % 0.23 [ 0.06, 0.97 ]
Spandorfer 2005 68/75 73/73 83.4 % 0.91 [ 0.84, 0.98 ]
Subtotal (95% CI) 120 127 100.0 % 0.91 [ 0.80, 1.02 ]
Total events: 79 (Intravenous), 87 (Subcutaneous)
Heterogeneity: Chi2 = 9.57, df = 4 (P = 0.05); I2 =58%
Test for overall effect: Z = 1.60 (P = 0.11)
2 Erythema
0.01 0.1 1 10 100
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(. . . Continued)
Study or subgroup Intravenous Subcutaneous Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Challiner 1994 0/17 1/17 2.1 % 0.33 [ 0.01, 7.65 ]
Harbo 2009 0/9 4/9 6.4 % 0.11 [ 0.01, 1.80 ]
Slesak 2003 11/48 10/48 14.1 % 1.10 [ 0.52, 2.35 ]
Spandorfer 2005 19/75 54/73 77.4 % 0.34 [ 0.23, 0.52 ]
Subtotal (95% CI) 149 147 100.0 % 0.43 [ 0.31, 0.61 ]
Total events: 30 (Intravenous), 69 (Subcutaneous)
Heterogeneity: Chi2 = 8.01, df = 3 (P = 0.05); I2 =63%
Test for overall effect: Z = 4.71 (P < 0.00001)
3 Swelling
Spandorfer 2005 16/75 59/73 100.0 % 0.26 [ 0.17, 0.41 ]
Subtotal (95% CI) 75 73 100.0 % 0.26 [ 0.17, 0.41 ]
Total events: 16 (Intravenous), 59 (Subcutaneous)
Heterogeneity: not applicable
Test for overall effect: Z = 5.82 (P < 0.00001)
4 Infection
Delamaire 1992 7/15 0/15 16.8 % 15.00 [ 0.93, 241.20 ]
Duems Noriega 2014 0/33 1/34 49.6 % 0.34 [ 0.01, 8.13 ]
Harbo 2009 1/9 0/9 16.8 % 3.00 [ 0.14, 65.16 ]
Slesak 2003 1/48 0/48 16.8 % 3.00 [ 0.13, 71.85 ]
Subtotal (95% CI) 105 106 100.0 % 3.70 [ 1.06, 12.88 ]
Total events: 9 (Intravenous), 1 (Subcutaneous)
Heterogeneity: Chi2 = 3.18, df = 3 (P = 0.37); I2 =6%
Test for overall effect: Z = 2.05 (P = 0.040)
5 Phlebitis
Duems Noriega 2014 2/33 0/34 24.7 % 5.15 [ 0.26, 103.33 ]
Harbo 2009 1/9 0/9 25.1 % 3.00 [ 0.14, 65.16 ]
Slesak 2003 6/48 1/48 50.2 % 6.00 [ 0.75, 47.97 ]
Subtotal (95% CI) 90 91 100.0 % 5.04 [ 1.14, 22.30 ]
Total events: 9 (Intravenous), 1 (Subcutaneous)
Heterogeneity: Chi2 = 0.14, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 2.13 (P = 0.033)
6 Oedema
Challiner 1994 0/17 1/19 3.7 % 0.37 [ 0.02, 8.53 ]
Delamaire 1992 0/15 3/15 9.2 % 0.14 [ 0.01, 2.55 ]
Duems Noriega 2014 2/33 5/34 13.0 % 0.41 [ 0.09, 1.98 ]
Harbo 2009 0/9 1/9 4.0 % 0.33 [ 0.02, 7.24 ]
O’Keeffe 1996 0/29 2/29 6.6 % 0.20 [ 0.01, 3.99 ]
Slesak 2003 11/48 19/48 50.1 % 0.58 [ 0.31, 1.08 ]
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(. . . Continued)
Study or subgroup Intravenous Subcutaneous Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Spandorfer 2005 1/75 5/73 13.4 % 0.19 [ 0.02, 1.63 ]
Subtotal (95% CI) 226 227 100.0 % 0.42 [ 0.25, 0.72 ]
Total events: 14 (Intravenous), 36 (Subcutaneous)
Heterogeneity: Chi2 = 2.30, df = 6 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 3.20 (P = 0.0014)
Test for subgroup differences: Chi2 = 56.53, df = 5 (P = 0.00), I2 =91%
0.01 0.1 1 10 100
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Analysis 2.8. Comparison 2 Intravenous versus subcutaneous access, Outcome 8 Local site reactions
(sensitivity analysis - trial(s) with adequate allocation concealment).
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 8 Local site reactions (sensitivity analysis - trial(s) with adequate allocation concealment)
Study or subgroup Intravenous Subcutaneous Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any
Challiner 1994 1/17 2/19 2.3 % 0.56 [ 0.06, 5.63 ]
Harbo 2009 3/9 6/9 7.3 % 0.50 [ 0.18, 1.40 ]
Spandorfer 2005 68/75 73/73 90.4 % 0.91 [ 0.84, 0.98 ]
Subtotal (95% CI) 101 101 100.0 % 0.87 [ 0.79, 0.96 ]
Total events: 72 (Intravenous), 81 (Subcutaneous)
Heterogeneity: Chi2 = 2.42, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 2.72 (P = 0.0065)
2 Erythema
Challiner 1994 0/17 1/17 2.5 % 0.33 [ 0.01, 7.65 ]
Harbo 2009 0/9 4/9 7.4 % 0.11 [ 0.01, 1.80 ]
Spandorfer 2005 19/75 54/73 90.1 % 0.34 [ 0.23, 0.52 ]
Subtotal (95% CI) 101 99 100.0 % 0.33 [ 0.22, 0.49 ]
0.01 0.1 1 10 100
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(. . . Continued)
Study or subgroup Intravenous Subcutaneous Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 19 (Intravenous), 59 (Subcutaneous)
Heterogeneity: Chi2 = 0.63, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 5.41 (P < 0.00001)
3 Swelling
Spandorfer 2005 16/75 59/73 100.0 % 0.26 [ 0.17, 0.41 ]
Subtotal (95% CI) 75 73 100.0 % 0.26 [ 0.17, 0.41 ]
Total events: 16 (Intravenous), 59 (Subcutaneous)
Heterogeneity: not applicable
Test for overall effect: Z = 5.82 (P < 0.00001)
4 Infection
Harbo 2009 1/9 0/9 100.0 % 3.00 [ 0.14, 65.16 ]
Subtotal (95% CI) 9 9 100.0 % 3.00 [ 0.14, 65.16 ]
Total events: 1 (Intravenous), 0 (Subcutaneous)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
5 Phlebitis
Harbo 2009 1/9 0/9 100.0 % 3.00 [ 0.14, 65.16 ]
Subtotal (95% CI) 9 9 100.0 % 3.00 [ 0.14, 65.16 ]
Total events: 1 (Intravenous), 0 (Subcutaneous)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
6 Oedema
Challiner 1994 0/17 1/19 17.8 % 0.37 [ 0.02, 8.53 ]
Harbo 2009 0/9 1/9 18.8 % 0.33 [ 0.02, 7.24 ]
Spandorfer 2005 1/75 5/73 63.4 % 0.19 [ 0.02, 1.63 ]
Subtotal (95% CI) 101 101 100.0 % 0.25 [ 0.06, 1.15 ]
Total events: 1 (Intravenous), 7 (Subcutaneous)
Heterogeneity: Chi2 = 0.15, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Chi2 = 48.28, df = 5 (P = 0.00), I2 =90%
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Analysis 2.9. Comparison 2 Intravenous versus subcutaneous access, Outcome 9 Clinicians’ scores of
feasibility of insertion.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 9 Clinicians’ scores of feasibility of insertion
Study or subgroup Intravenous Subcutaneous
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Doctors’ scores
Slesak 2003 48 2 (0.47) 48 2 (0.19) 0.0 [ -0.14, 0.14 ]
2 Nurses’ scores
Slesak 2003 43 2 (0.313) 44 2 (0.25) 0.0 [ -0.12, 0.12 ]
-0.2 -0.1 0 0.1 0.2
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Analysis 2.10. Comparison 2 Intravenous versus subcutaneous access, Outcome 10 Clinician’s perception of
difficulty of insertion.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 10 Clinician’s perception of difficulty of insertion
Study or subgroup Intravenous Subcutaneous Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Spandorfer 2005 26/75 4/73 6.33 [ 2.32, 17.23 ]
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Analysis 2.11. Comparison 2 Intravenous versus subcutaneous access, Outcome 11 Patients’ discomfort.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 11 Patients’ discomfort
Study or subgroup Intravenous Subcutaneous Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pain
Harbo 2009 0/9 3/9 5.3 % 0.14 [ 0.01, 2.42 ]
Slesak 2003 8/48 6/48 9.1 % 1.33 [ 0.50, 3.55 ]
Spandorfer 2005 59/75 56/73 85.7 % 1.03 [ 0.86, 1.22 ]
Subtotal (95% CI) 132 130 100.0 % 1.01 [ 0.83, 1.22 ]
Total events: 67 (Intravenous), 65 (Subcutaneous)
Heterogeneity: Chi2 = 2.19, df = 2 (P = 0.33); I2 =9%
Test for overall effect: Z = 0.07 (P = 0.94)
2 Agitation
Duems Noriega 2014 16/33 11/34 49.6 % 1.50 [ 0.82, 2.73 ]
O’Keeffe 1996 24/29 11/29 50.4 % 2.18 [ 1.33, 3.58 ]
Subtotal (95% CI) 62 63 100.0 % 1.84 [ 1.26, 2.70 ]
Total events: 40 (Intravenous), 22 (Subcutaneous)
Heterogeneity: Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 3.14 (P = 0.0017)
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Analysis 2.12. Comparison 2 Intravenous versus subcutaneous access, Outcome 12 Patients’ discomfort
(sensitivity analysis - trial(s) with adequate allocation concealment).
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 12 Patients’ discomfort (sensitivity analysis - trial(s) with adequate allocation concealment)
Study or subgroup Intravenous Subcutaneous Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pain
Harbo 2009 0/9 3/9 5.8 % 0.14 [ 0.01, 2.42 ]
Spandorfer 2005 59/75 56/73 94.2 % 1.03 [ 0.86, 1.22 ]
Subtotal (95% CI) 84 82 100.0 % 0.97 [ 0.81, 1.16 ]
Total events: 59 (Intravenous), 59 (Subcutaneous)
Heterogeneity: Chi2 = 2.11, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 0.29 (P = 0.77)
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Analysis 2.13. Comparison 2 Intravenous versus subcutaneous access, Outcome 13 Patient discomfort
score.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 13 Patient discomfort score
Study or subgroup Intravenous Subcutaneous
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Slesak 2003 28 2 (0.5) 26 2 (0.25) 0.0 [ -0.21, 0.21 ]
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Analysis 2.14. Comparison 2 Intravenous versus subcutaneous access, Outcome 14 Mortality.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 14 Mortality
Study or subgroup Intravenous Subcutaneous Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Challiner 1994 0/17 1/19 58.7 % 0.37 [ 0.02, 8.53 ]
Duems Noriega 2014 2/35 1/35 41.3 % 2.00 [ 0.19, 21.06 ]
Total (95% CI) 52 54 100.0 % 1.04 [ 0.18, 5.92 ]
Total events: 2 (Intravenous), 2 (Subcutaneous)
Heterogeneity: Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 2.15. Comparison 2 Intravenous versus subcutaneous access, Outcome 15 Mortality (sensitivity
analysis - trial(s) with adequate allocation concealment).
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 15 Mortality (sensitivity analysis - trial(s) with adequate allocation concealment)
Study or subgroup Intravenous Subcutaneous Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Challiner 1994 0/17 1/19 0.37 [ 0.02, 8.53 ]
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Analysis 2.16. Comparison 2 Intravenous versus subcutaneous access, Outcome 16 Volume of fluids
transfused.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 16 Volume of fluids transfused
Study or subgroup Intravenous Subcutaneous
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Duems Noriega 2014 33 1480 (340) 34 1320 (400) 160.00 [ -17.58, 337.58 ]
O’Keeffe 1996 29 760 (140) 29 820 (120) -60.00 [ -127.11, 7.11 ]
Slesak 2003 48 1000 (250) 48 750 (260.8) 250.00 [ 147.80, 352.20 ]
Spandorfer 2005 75 455.8 (597.4) 73 365 (324.6) 90.80 [ -63.55, 245.15 ]
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Analysis 2.17. Comparison 2 Intravenous versus subcutaneous access, Outcome 17 Volume of fluids
transfused (sensitivity analysis - trial(s) with adequate allocation).
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 17 Volume of fluids transfused (sensitivity analysis - trial(s) with adequate allocation)
Study or subgroup Intravenous Subcutaneous
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Spandorfer 2005 75 455.8 (597.4) 73 365 (324.6) 90.80 [ -63.55, 245.15 ]
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Analysis 2.18. Comparison 2 Intravenous versus subcutaneous access, Outcome 18 Electrolyte level.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 18 Electrolyte level
Study or subgroup Intravenous Subcutaneous
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sodium
Slesak 2003 37 139 (5) 40 137 (5) 2.00 [ -0.24, 4.24 ]
-10 -5 0 5 10
Higher in subcutaneous Higher in intravenous
Analysis 2.19. Comparison 2 Intravenous versus subcutaneous access, Outcome 19 Markers of renal
function.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 2 Intravenous versus subcutaneous access
Outcome: 19 Markers of renal function
Study or subgroup Intravenous Subcutaneous
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Urea
Duems Noriega 2014 33 52.3 (23.8) 34 63.59 (31.7) 100.0 % -11.29 [ -24.69, 2.11 ]
Subtotal (95% CI) 33 34 100.0 % -11.29 [ -24.69, 2.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
2 Creatinine
Duems Noriega 2014 33 0.6 (0.49) 34 0.68 (0.66) 79.8 % -0.08 [ -0.36, 0.20 ]
Slesak 2003 31 0.8 (0.73) 40 0.9 (1.58) 20.2 % -0.10 [ -0.65, 0.45 ]
Subtotal (95% CI) 64 74 100.0 % -0.08 [ -0.33, 0.16 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Chi2 = 2.69, df = 1 (P = 0.10), I2 =63%
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Analysis 3.1. Comparison 3 Saphenous vein cutdown versus intraosseous access, Outcome 1 Insertion
failures.
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 3 Saphenous vein cutdown versus intraosseous access
Outcome: 1 Insertion failures
Study or subgroup
Saphenous
vein
cutdown Intraosseous Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hubble 2001 4/13 1/13 4.00 [ 0.51, 31.13 ]
0.002 0.1 1 10 500
Favours Saphenous vein cutdown Favours intraosseous
Analysis 3.2. Comparison 3 Saphenous vein cutdown versus intraosseous access, Outcome 2 Time to
infusion/placement (seconds).
Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
Comparison: 3 Saphenous vein cutdown versus intraosseous access
Outcome: 2 Time to infusion/placement (seconds)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Hubble 2001 219.6 (42.94) 219.60 [ 135.44, 303.76 ]
-500 -250 0 250 500
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A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Injuries Group Specialised Register & Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane
Library)
#1((Intravenous or venous) ADJ3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat*
or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)):TI,AB,KY
#2MESH DESCRIPTOR Infusions, Intravenous
#3#1 OR #2
#4((intraperitoneal*) ADJ3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or
infus* or dehydrat* or hydrat* or rehydrat* or drug* or medication*)):TI,AB,KY
#5MESH DESCRIPTOR Infusions, Intraosseous
#6(intraosseous*) ADJ3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus*
or dehydrat* or rehydrat* or hydrat* or drug* or medication*)
#7#5 OR #6
#8MESH DESCRIPTOR Infusions, Subcutaneous
#9MESH DESCRIPTOR Hypodermoclysis
#10((subcutaneous* or hypodermoclysis) ADJ3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer*
or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)):TI,AB,KY
#11#8 OR #9 OR #10
#12#4 OR #7 OR #11
#13#3 AND #12
#14#3 OR #7 OR #11
#15#4 AND #14
#16#3 OR #4 OR #11
#17#7 AND #16
#18#3 OR #4 OR #7
#19#11 AND #18
#20#13 OR #15 OR #17 OR #19
#21* NOT INMEDLINE NOT INEMBASE
#22#20 AND #21
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily, Ovid MEDLINE(R) and Ovid
OLDMEDLINE(R)
1. Infusions, Intravenous/
2. ((“intra?venous*” or venous) adj3 (route* or access* or insert* or device* ormethod* or fluid* or therap* or administer* or administrat*
or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)).ab,ti.
3. 1 or 2
4. (“intra?peritoneal*” adj3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or
infus* or dehydrat* or hydrat* or rehydrat* or drug* or medication*)).ab,ti.
5. Infusions, Intraosseous/
6. (“intra?osseous*” adj3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus*
or dehydrat* or rehydrat* or hydrat* or drug* or medication*)).ab,ti.
7. 5 or 6
8. infusions, subcutaneous/ or hypodermoclysis/
9. ((subcutaneous* or subcut or hypodermoclysis) adj3 (route* or access* or insert* or device* or method* or fluid* or therap* or
administer* or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)).ab,ti.
10. 8 or 9
11. 4 or 7 or 10
12. 3 and 11
13. 3 or 7 or 10
14. 4 and 13
15. 3 or 4 or 10
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16. 7 and 15
17. 3 or 4 or 7
18. 10 and 17
19. 12 or 14 or 16 or 18
20. randomi?ed.ab,ti.
21. randomized controlled trial.pt.
22. controlled clinical trial.pt.
23. placebo.ab.
24. clinical trials as topic.sh.
25. randomly.ab.
26. trial.ti.
27. Comparative Study/
28. 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
29. (animals not (humans and animals)).sh.
30. 28 not 29
31. 19 and 30
Embase + Embase Classic
1. Infusions, Intravenous/
2. ((“intra?venous*” or venous) adj3 (route* or access* or insert* or device* ormethod* or fluid* or therap* or administer* or administrat*
or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)).ab,ti.
3. 1 or 2
4. (“intra?peritoneal*” adj3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or
infus* or dehydrat* or hydrat* or rehydrat* or drug* or medication*)).ab,ti.
5. Infusions, Intraosseous/
6. (“intra?osseous*” adj3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus*
or dehydrat* or rehydrat* or hydrat* or drug* or medication*)).ab,ti.
7. 5 or 6
8. infusions, subcutaneous/ or hypodermoclysis/
9. ((subcutaneous* or subcut or hypodermoclysis) adj3 (route* or access* or insert* or device* or method* or fluid* or therap* or
administer* or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)).ab,ti.
10. 8 or 9
11. 4 or 7 or 10
12. 3 and 11
13. 3 or 7 or 10
14. 4 and 13
15. 3 or 4 or 10
16. 7 and 15
17. 3 or 4 or 7
18. 10 and 17
19. 12 or 14 or 16 or 18
20. exp Randomized Controlled Trial/
21. exp controlled clinical trial/
22. exp controlled study/
23. comparative study/
24. randomi?ed.ab,ti.
25. placebo.ab.
26. *Clinical Trial/
27. exp major clinical study/
28. randomly.ab.
29. (trial or study).ti.
30. 20 or 21 or 22 or 24 or 25 or 26 or 27 or 28 or 29
31. exp animal/ not (exp human/ and exp animal/)
32. 30 not 31
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33. 19 and 32
34. limit 33 to exclude medline journals
CINAHL Plus (EBSCO)
S1 (MH “Clinical Trials”)
S2 PT clinical trial*
S3 TX clinical N3 trial*
S4 TI ( (singl* N3 blind*) or (doubl* N3 blind*) or (trebl* N3 blind*) or (tripl* N3 blind*) ) or TI ( (singl* N3 mask*) or (doubl*
N3 mask*) or (trebl* N3 mask*) or (tripl* N3 mask*) ) or AB ( (singl* N3 blind*) or (doubl* N3 blind*) or (trebl* N3 blind*)
) or AB ( (singl* N3 mask*) or (doubl* N3 mask*) or (trebl* N3 mask*) or (tripl* N3 mask*) )
S5 TX randomi?ed N3 control* N3 trial*
S6 (MH “Placebos”)
S7 TX placebo*
S8 (MH “Random Assignment”)
S9 TX random* N3 allocat*
S10 MH quantitative studies
S11 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10
S12 (MH “Infusions, Intravenous”)
S13 TI (intravenous N3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or
infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*))
S14 AB (intravenous N3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or
infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*))
S15 S12 OR S13 OR S14
S16 TI intraperitoneal*“ N3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat*
or infus* or dehydrat* or hydrat* or rehydrat* or drug* or medication*)
S17 AB intraperitoneal*” N3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat*
or infus* or dehydrat* or hydrat* or rehydrat* or drug* or medication*)
S18 S16 OR S17
S19 (MH “Infusions, Intraosseous”)
S20 TI intraosseous* N3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or
infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)
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(Continued)
S21 AB intraosseous* N3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or
infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)
S22 S19 OR S20 OR S21
S23 (MH “Infusions, Subcutaneous”)
S24 (MH “Hypodermoclysis”)
S25 TI (subcutaneous* or hypodermoclysis)N3 (route* or access* or insert* or device* ormethod* or fluid* or therap* or administer*
or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)
S26 AB (subcutaneous* or hypodermoclysis) N3 (route* or access* or insert* or device* or method* or fluid* or therap* or
administer* or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)
S27 S23 OR S24 OR S25 OR S26
S28 S18 OR S22 OR S27
S29 S15 AND S28
S30 S15 OR S22 OR S27
S31 S18 AND S30
S32 S15 OR S18 OR S27
S33 S22 AND S32
S34 S15 OR S18 OR S22
S35 S27 AND S34
S36 S29 OR S31 OR S33 OR S35
S37 S11 AND S36 Limiters - Exclude MEDLINE records
Clinicaltrials.gov
( subcutaneous OR rectal OR proctoclysis OR intraosseous ) AND INFLECT EXACT “Interventional” [STUDY-TYPES] ANDfluids
[TREATMENT]
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Appendix 2. Formulae to estimate mean and standard deviation from median, range and sample
size as recommended by Hozo et al
Estimation of mean
If sample size is > 25, median can be used to estimate mean.
Estimation of standard deviation (SD)
If moderate sample size (15 < n ≤ 70) estimated SD = range/4.
If large sample size (n > 70) estimated SD = range/6.
(Hozo 2005).
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We added further details to the Types of studies and Types of participants sections. These changes do not represent a change in the
inclusion criteria between the protocol and review, but have been made based on the recommendations in editorial comments on the
completed review to improve clarity.
We have included a paragraph to describe how data from cluster-randomised controlled trials would be included in the analysis.
At the request of the Cochrane Editorial Unit editors, we refined the outcomes included in the ’Summary of findings’ tables and
GRADE assessment. Rather than including all outcomes as originally proposed, only outcomes most closely aligned with the objectives
of the review are included (success of route of placement; time to placement/start of infusion; dislodgement of device during infusion;
volume of fluid infused and needlestick injuries).
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